JANL 10-Q Quarterly Report March 31, 2020 | Alphaminr
ALPHAMINR

JANL 10-Q Quarter ended March 31, 2020

Balance Sheet
Cash Flow
Income Statement
JANEL CORP
10-Ks and 10-Qs
10-Q
Quarter ended June 30, 2025
10-Q
Quarter ended March 31, 2025
10-Q
Quarter ended Dec. 31, 2024
10-K
Fiscal year ended Sept. 30, 2024
10-Q
Quarter ended June 30, 2024
10-Q
Quarter ended March 31, 2024
10-Q
Quarter ended Dec. 31, 2023
10-K
Fiscal year ended Sept. 30, 2023
10-Q
Quarter ended June 30, 2023
10-Q
Quarter ended March 31, 2023
10-Q
Quarter ended Dec. 31, 2022
10-K
Fiscal year ended Sept. 30, 2022
10-Q
Quarter ended June 30, 2022
10-Q
Quarter ended March 31, 2022
10-Q
Quarter ended Dec. 31, 2021
10-K
Fiscal year ended Sept. 30, 2021
10-Q
Quarter ended June 30, 2021
10-Q
Quarter ended March 31, 2021
10-Q
Quarter ended Dec. 31, 2020
10-K
Fiscal year ended Sept. 30, 2020
10-Q
Quarter ended June 30, 2020
10-Q
Quarter ended March 31, 2020
10-Q
Quarter ended Dec. 31, 2019
10-K
Fiscal year ended Sept. 30, 2019
10-Q
Quarter ended June 30, 2019
10-Q
Quarter ended March 31, 2019
10-Q
Quarter ended Dec. 31, 2018
10-K
Fiscal year ended Sept. 30, 2018
10-Q
Quarter ended June 30, 2018
10-Q
Quarter ended March 31, 2018
10-Q
Quarter ended Dec. 31, 2017
10-K
Fiscal year ended Sept. 30, 2017
10-Q
Quarter ended June 30, 2017
10-Q
Quarter ended March 31, 2017
10-Q
Quarter ended Dec. 31, 2016
10-K
Fiscal year ended Sept. 30, 2016
10-Q
Quarter ended June 30, 2016
10-Q
Quarter ended March 31, 2016
10-Q
Quarter ended Dec. 31, 2015
10-K
Fiscal year ended Sept. 30, 2015
10-Q
Quarter ended June 30, 2015
10-Q
Quarter ended March 31, 2015
10-Q
Quarter ended Dec. 31, 2014
10-K
Fiscal year ended Sept. 30, 2014
10-Q
Quarter ended June 30, 2014
10-Q
Quarter ended March 31, 2014
10-Q
Quarter ended Dec. 31, 2013
10-K
Fiscal year ended Sept. 30, 2013
10-Q
Quarter ended June 30, 2013
10-Q
Quarter ended March 31, 2013
10-Q
Quarter ended Dec. 31, 2012
10-K
Fiscal year ended Sept. 30, 2012
10-Q
Quarter ended June 30, 2012
10-Q
Quarter ended March 31, 2012
10-Q
Quarter ended Dec. 31, 2011
10-K
Fiscal year ended Sept. 30, 2011
10-Q
Quarter ended June 30, 2011
10-Q
Quarter ended March 31, 2011
10-Q
Quarter ended Dec. 31, 2010
10-K
Fiscal year ended Sept. 30, 2010
10-Q
Quarter ended June 30, 2010
10-Q
Quarter ended March 31, 2010
10-Q
Quarter ended Dec. 31, 2009
10-K
Fiscal year ended Sept. 30, 2009
10-Q 1 form10q.htm 10-Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2020
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____ to ____
Commission file number: 333-60608
JANEL CORPORATION
(Exact name of registrant as specified in its charter)
Nevada
86-1005291
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)

80 Eighth Avenue
New York, New York
10011
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code: (516) 256-8143
Former name, former address and former fiscal year, if changed from last report: N/A
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading symbols(s)
Name of each exchange
on which registered
None
None
None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ☒   No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes ☒   No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
Accelerated filer
☐
Non-accelerated filer ☐
Smaller reporting company
☒
Emerging growth company
☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
Yes ☐  No ☒
The number of shares of Common Stock outstanding as of May 11, 2020 was 850,652.
JANEL CORPORATION
QUARTERLY REPORT ON FORM 10-Q
For Quarterly Period Ended March 31, 2020
TABLE OF CONTENTS
Page
3
Item 1.
3
3
4
5
6
7
Item 2.
26
Item 4.
39
41
Item 1.
41
Item 1A.
42
Item 2.
43
Item 6.
43
44

PART I - FINANCIAL INFORMATION
ITEM 1.
FINANCIAL STATEMENTS
JANEL CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(dollars in thousands, except share and per share data)
March 31, 2020
(Unaudited)
September 30,
2019
ASSETS
Current Assets:
Cash
$
1,928
$
2,163
Accounts receivable, net of allowance for doubtful accounts
13,677
21,351
Inventory, net
4,178
4,371
Prepaid expenses and other current assets
349
531
Note receivable
142
139
Total current assets
20,274
28,555
Property and Equipment, net
3,992
3,954
Other Assets:
Intangible assets, net
13,112
13,598
Goodwill
13,641
13,525
Operating lease right of use asset
1,599
—
Security deposits and other long term assets
250
87
Total other assets
28,602
27,210
Total assets
$
52,868
$
59,719
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current Liabilities:
Line of credit
$
7,533
$
8,391
Accounts payable – trade
15,314
22,061
Accrued expenses and other current liabilities
2,891
2,272
Dividends payable
1,366
1,041
Current portion of operating lease liabilities
479
—
Current portion of subordinated promissory note
155
152
Current portion of long-term debt
838
828
Total current liabilities
28,576
34,745
Other Liabilities:
Long-term debt
6,310
6,602
Subordinated promissory notes
465
541
Mandatorily redeemable non-controlling interest
619
619
Deferred income taxes
1,817
2,000
Long term operating lease liabilities
1,142
—
Other liabilities
302
334
Total other liabilities
10,655
10,096
Total liabilities
39,231
44,841
Stockholders’ Equity:
Preferred Stock, $0.001 par value; 100,000 shares authorized


Series B 5,700 shares authorized and 631 shares issued and outstanding as of March 31, 2020 and September 30, 2019, respectively
—
—
Series C 20,000 shares authorized and 20,000 shares issued and outstanding at March 31, 2020 and September 30, 2019, liquidation value of $12,867 and $12,541 at March 31, 2020 and September 30, 2019, respectively
—
—
Common stock, $0.001 par value; 4,500,000 shares authorized, 867,652 issued and 847,652 outstanding as of March 31, 2020 and 863,812 issued and 843,812 outstanding as of September 30, 2019
1
1
Paid-in capital
14,891
15,075
Treasury stock, at cost, 20,000 shares
(240
)
(240
)
Accumulated (deficit) earnings
(1,015
)
42
Total stockholders’ equity
13,637
14,878
Total liabilities and stockholders’ equity
$
52,868
$
59,719

The accompanying notes are an integral part of these consolidated financial statements.

JANEL CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except share and per share data)
(Unaudited)
Three Months Ended
March 31,
Six Months Ended
March 31,
2020
2019
2020
2019
Revenue
$
19,121
$
20,969
$
38,942
$
43,296
Forwarding expenses and cost of revenues
13,125
14,599
26,659
30,439
Gross profit
5,996
6,370
12,283
12,857
Cost and Expenses:
Selling, general and administrative
6,584
5,692
12,669
11,081
Amortization of intangible assets
243
236
486
444
Total Costs and Expenses
6,827
5,928
13,155
11,525
(Loss) Income from Operations
(831
)
442
(872
)
1,332
Other Items:
Interest expense net of interest income
(141
)
(198
)
(304
)
(360
)
(Loss) Income Before Income Taxes
(972
)
244
(1,176
)
972
Income tax benefit (expense)
35
(69
)
119
(253
)
Net (Loss) Income
(937
)
175
(1,057
)
719
Preferred stock dividends
(175
)
(148
)
(326
)
(270
)
Net (Loss) Income Available to Common Stockholders
$
(1,112
)
$
27
$
(1,383
)
$
449
Net (loss) Income per share
Basic
$
(1.08
)
$
0.21
$
(1.22
)
$
0.85
Diluted
$
(1.08
)
$
0.18
$
(1.22
)
$
0.77
Net (loss) income per share attributable to common stockholders:
Basic
$
(1.29
)
$
0.04
$
(1.60
)
$
0.53
Diluted
$
(1.29
)
$
0.03
$
(1.60
)
$
0.48
Weighted average number of shares outstanding:
Basic
865,985
847,784
865,630
847,621
Diluted
865,985
931,960
865,630
934,137
The accompanying notes are an integral part of these consolidated financial statements.
JANEL CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY
(in thousands, except share and per share data)
(Unaudited)

PREFERRED STOCK
COMMON STOCK
PAID-IN
CAPITAL
TREASURY STOCK
ACCUMULATED
EARNINGS
(DEFICIT)
TOTAL
EQUITY
SHARES
$
SHARES
$
$
SHARES
$
$
$
Balance - September 30, 2019
20,631
$
—
863,812
$
1
$
15,075
20,000
$
(240
)
$
42
$
14,878
Net Loss
—
—
—
—
—
—
—
(1,057
)
(1,057
)
Dividends to preferred stockholders
—
—
—
—
(326
)
—
—
—
(326
)
Stock-based compensation
—
—
—
—
111
—
—
—
111
Stock option exercise
—
—
3,840
—
31
—
—
—
31
Balance - March 31, 2020
20,631
$
—
867,652
$
1
$
14,891
20,000
$
(240
)
$
(1,015
)
$
13,637

PREFERRED STOCK
COMMON STOCK
PAID-IN
CAPITAL
TREASURY STOCK
ACCUMULATED
EARNINGS
(DEFICIT)
TOTAL
EQUITY
SHARES
$
SHARES
$
$
SHARES
$
$
$
Balance -September 30, 2018
21,271
$
—
837,951
$
1
$
15,872
20,000
$
(240
)
$
(606
)
$
15,027
Net Income
—
—
—
—
—
—
—
719
719
Cumulative effect of change in accounting principle
—
—
—
—
—
—
—
32
32
Dividends to preferred stockholders
—
—
—
—
(270
)
—
—
—
(270
)
Vested restricted stock unissued
—
—
—
—
(236
)
—
—
—
(236
)
Stock option exercise
—
—
1,500
—
5
—
—
—
5
Stock-based compensation
—
—
—
—
172
—
—
—
172
Balance - March 31, 2019
21,271
$
—
839,451
$
1
$
15,543
20,000
$
(240
)
$
145
$
15,449

The accompanying notes are an integral part of these consolidated financial statements .
JANEL CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
Six Months Ended
March 31,
2020
2019
Cash Flows From Operating Activities:
Net (loss) income
$
(1,057
)
$
719
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Provision for uncollectible accounts
164
330
Depreciation
92
152
Deferred income tax
(183
)
302
Amortization of intangible assets
486
444
Amortization of acquired inventory valuation
447
129
Amortization of loan costs
14
5
Stock-based compensation
149
236
Changes in operating assets and liabilities, net of effects of acquisitions:
Accounts receivable
7,510
(1,002
)
Inventory
(254
)
(131
)
Prepaid expenses and other current assets
182
(134
)
Security deposits and other long term assets
(166
)
(5
)
Accounts payable and accrued expenses
(6,166
)
171
Lease liability
5
-
Other liabilities
(14
)
56
Net cash provided by operating activities
1,209
1,272
Cash Flows From Investing Activities:
Acquisition of property and equipment, net of disposals
(131
)
(253
)
Acquisitions
(116
)
(1,935
)
Net cash used in investing activities
(247
)
(2,188
)
Cash Flows From Financing Activities:
Repayments of term loan
(282
)
(491
)
Proceeds from stock option exercise
31
5
Line of credit, proceeds, net
(873
)
2,234
Repayment of subordinated promissory notes
(73
)
(36
)
Net cash (used in) provided by financing activities
(1,197
)
1,712
Net (decrease) increase in cash
(235
)
796
Cash at beginning of the period
2,163
585
Cash at end of period
$
1,928
$
1,381
Supplemental Disclosure of Cash Flow Information:
Cash paid during the period for :
Interest
$
309
$
360
Income taxes
$
9
$
81
Non-cash operating activities: Operating lease right of use asset
$
1,900
$
—
Operating lease liabilities Non-cash investing activities :
$
1,917
$
—
Contingent earn-out acquisition
$
—
$
50
Subordinated Promissory notes of Honor
$
—
$
456
Non-cash financing activities :
Dividends declared to preferred stockholders
$
326
$
270
Vested restricted stock unissued
$
—
$
236

The accompanying notes are an integral part of these consolidated financial statements.
JANEL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(in thousands, except share and per share data)
1.
BASIS OF PRESENTATION, SUMMARY OF BUSINESS AND SIGNIFICANT ACCOUNTING POLICIES
The accompanying interim unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of Article 8 of Regulation S-X and the instructions to Form 10-Q of the Securities and Exchange Commission. As a result, certain information and footnote disclosures normally included in audited financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. Janel Corporation (the “Company” or “Janel”) believes that the disclosures made are adequate to make the information presented not misleading. The consolidated financial statements reflect all adjustments which are, in the opinion of management, necessary to a fair statement of the results for the interim periods presented. The results of operations for the periods presented are not necessarily indicative of the results to be expected for a full fiscal year, or any other period. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes included in the Company’s Form 10-K as filed with the Securities and Exchange Commission.
Business description
Janel is a holding company with subsidiaries in three business segments: Global Logistics Services, Manufacturing and Life Sciences. A management group at the holding company level (the “corporate group”) focuses on significant capital allocation decisions, corporate governance and supporting Janel’s subsidiaries where appropriate. Janel expects to grow through its subsidiaries’ organic growth and by completing acquisitions. We plan to either acquire businesses within our existing segments or expand our portfolio into new strategic segments. Our acquisition strategy focuses on reasonably priced companies with strong and capable management teams, attractive existing business economics and stable and predictable earnings power.
Global Logistics Services
The Company’s Global Logistics Services segment is comprised of several wholly-owned subsidiaries, collectively known as “Janel Group.” Janel Group is a non-asset based, full-service provider of cargo transportation logistics management services, including freight forwarding via air-, ocean- and land-based carriers, customs brokerage services, warehousing and distribution services, and other value-added logistics services.
On November 20, 2018, we completed a business combination whereby we acquired the membership interest of Honor Worldwide Logistics, LLC (“Honor”), a global logistics services provider with two U.S. locations. See note 2.
On October 17, 2018, we completed a business combination whereby we acquired substantially all of the assets and certain liabilities of a global logistics services provider with one U.S. location. See note 2.
Manufacturing
The Company’s manufacturing segment is comprised of Indco, Inc. (“Indco”), a majority-owned subsidiary of the Company that manufactures and distributes mixing equipment and apparatus for specific applications within various industries. Indco’s customer base is comprised of small- to mid-sized businesses as well as other larger customers for which Indco fulfills repetitive production orders.
Life Sciences
The Company’s Life Sciences segment is comprised of Aves Labs, Inc. (“Aves”), Antibodies Incorporated (“Antibodies”), IgG, LLC (“IgG”) and PhosphoSolutions, LLC, which are wholly-owned subsidiaries of the Company.
The Company’s Life Sciences segment manufactures and distributes high-quality monoclonal and polyclonal antibodies, diagnostic reagents and other immunoreagents for biomedical research and provides antibody manufacturing for academic and industry research scientists. Our Life Sciences business also produces products for other life science companies on an original equipment manufacturer (“OEM”) basis.
Through Aves, the Company acquired the membership interests of a small life sciences company on July 1, 2019 and the equity interests of PhosphoSolutions, LLC. (“Phospho”) on September 6, 2019. Both acquisitions were completed primarily to expand our product offerings in Life Sciences. See note 2.
Basis of consolidation
The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, as well as Indco, of which Janel owns 91.65%, with a non-controlling interest held by existing Indco management. The Indco non-controlling interest is mandatorily redeemable and is recorded as a liability. All intercompany transactions and balances have been eliminated in consolidation.
Uses of estimates in the preparation of financial statements
The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of financial statements, as well as the reported amounts of revenues and expenses during the reporting period. The most critical estimates made by the Company are those relating to accounts receivables valuation, the useful lives of long-term assets, accrual of cost related to ancillary services the Company provides and accrual of tax expense on an interim basis.
Cash
The Company maintains cash balances at various financial institutions. Accounts at each institution are insured by the Federal Deposit Insurance Corporation up to $250. The Company’s accounts at these institutions may, at times, exceed the federally insured limits. The Company has not experienced any losses in such accounts.
Accounts receivable and allowance for doubtful accounts receivable
Accounts receivable are recorded at the contractual amount. The Company records its allowance for doubtful accounts based upon its assessment of various factors. The Company considers historical collection experience, the age of the accounts receivable balances, credit quality of the Company’s customers, any specific customer collection issues that have been identified, current economic conditions, and other factors that may affect the customers’ ability to pay. The Company writes off accounts receivable balances that have aged significantly once all collection efforts have been exhausted and the receivables are no longer deemed collectible from the customer. The allowance for doubtful accounts as of March 31, 2020 and September 30, 2019 was $654 and $503, respectively.
Inventory
Inventory is valued at the lower of cost (using the first-in, first-out method) or net realizable value. The Company maintains an inventory valuation reserve to provide for slow moving and obsolete inventory, inventory not meeting quality control standards and inventory subject to expiration for its Antibodies business. The products of Antibodies require the initial manufacture of multiple batches to determine if quality standards can consistently be met. In addition, the Company will produce larger batches of established products than current sales requirements due to economies of scale. The manufacturing process for these products, therefore, has and will continue to produce quantities in excess of forecasted usage. The Company values acquired manufactured antibody inventory based on a three-year forecast. Inventory quantities in excess of the forecast are not valued due to uncertainty over salability. Amounts are charged to the reserve when the Company scraps or disposes of inventory.
Property and equipment and depreciation policy
Property and equipment are recorded at cost. Property and equipment acquired in business combinations are initially recorded at fair value. Depreciation is provided for in amounts sufficient to amortize the costs of the related assets over their estimated useful lives on the straight-line and accelerated methods for both financial reporting and income tax purposes.
Maintenance and repairs are recorded as expenses when incurred.
Goodwill
The Company records as goodwill the excess of purchase price over the fair value of the tangible and identifiable intangible assets acquired in a business combination. Under current authoritative guidance, goodwill is not amortized but is tested for impairment annually (on September 30) as well as when an event or change in circumstance indicates impairment may have occurred. Goodwill is tested for impairment by comparing the fair value of the Company’s individual reporting units to their carrying amount to determine if there is potential goodwill impairment. If the fair value of the reporting unit is less than the carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill of the reporting unit is less than its carrying value. If there is a material change in economic conditions, including as a result of continued disruption due to the coronavirus (COVID-19) pandemic, or other circumstances influencing the estimate of future cash flows or significantly affect the fair value of our reporting units, the Company could be required to recognize impairment charges in the future. There were no indicators of impairment of goodwill as of March 21, 2020 and September 30, 2019.
The fair value of our reporting units was in excess of carrying value and goodwill was not deemed to be impaired as of March 31, 2020 and September 30, 2019.
Intangibles and long-lived assets
Long-lived assets, including fixed assets and intangible assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable. In reviewing for impairment, the carrying value of such assets is compared to the estimated undiscounted future cash flows expected from the use of the assets and their eventual disposition.
If such cash flows are not sufficient to support the asset’s recorded value, an impairment charge is recognized to reduce the carrying value of the long-lived asset to its estimated fair value. The determination of future cash flows, as well as the estimated fair value of long-lived assets, involves significant estimates on the part of management. If there is a material change in economic conditions, including as a result of continued disruption due to the coronavirus (COVID-19) pandemic, or other circumstances influencing the estimate of future cash flows or fair value, the Company could be required to recognize impairment charges in the future. There were no indicators of impairment of long-lived assets as of March 31, 2020 and September 30, 2019.
Business segment information
The Company operates in three reportable segments: Global Logistics Services, Manufacturing and Life Sciences. The Company’s Chief Executive Officer regularly reviews financial information at the reporting segment level in order to make decisions about resources to be allocated to the segments and to assess their performance.
Revenues and revenue recognition
Adoption of ASC Topic 606, “Revenue from Contracts with Customers”
On October 1, 2018, the Company adopted ASU 2014-09, Revenue from Contracts with Customers (“ASC Topic 606”), using the modified retrospective method. Results for reporting periods beginning on or after October 1, 2018 are presented under ASC Topic 606; however, prior period amounts are not adjusted and continue to be reported in accordance with the accounting standards in effect for those periods.
The Company recorded an increase to the opening balance of retained earnings of $32, net of tax, as of October 1, 2018 due to the cumulative impact of adoption of ASC Topic 606. The impact to revenue and associated cost for the six months ended March 31, 2019 was an increase of $218 and $177, respectively, as a result of applying ASC Topic 606.
Global Logistics Services
Revenue Recognition
Revenue is recognized upon transfer of control of promised services to customers. With respect to its Global Logistics Services segment, the Company has determined that in general each shipment transaction or service order constitutes a separate contract with the customer. When the Company provides multiple services to a customer, different contracts may be present for different services.
The Company typically satisfies its performance obligations as services are rendered at a point in time. A typical shipment would include services rendered at origin, such as pick-up and delivery to port, freight services from origin to destination port and destination services, such as customs clearance and final delivery. The Company measures the performance of its obligations as services are completed at a point in time during the life of a shipment, including services at origin, freight and destination. The Company fulfills nearly all of its performance obligations within a one to two-month period.
The Company evaluates whether amounts billed to customers should be reported as gross or net revenue. Generally, revenue is recorded on a gross basis when the Company is primarily responsible for fulfilling the promise to provide the services, when it has discretion in setting the prices for the services to the customers, and the Company has the ability to direct the use of the services provided by the third party. Revenue is recognized on a net basis when we do not have latitude in carrier selection or to establish rates with the carrier.
In the Global Logistics Services segment, the Company disaggregates its revenues by its four primary service categories: ocean import and export, freight forwarding, customs brokerage and air import and export. A summary of the Company’s revenues disaggregated by major service lines for the three and six months ended March 31, 2020 was as follows:
Three Months Ended
March 31,
Six Months Ended
March 31,
Service Type
2020
2020
Ocean import and export
$
5,880
$
11,737
Freight forwarding
2,653
6,462
Customs brokerage
3,111
5,305
Air import and export
3,684
7,903
Total
$
15,328
$
31,407

Manufacturing
Revenues from Indco are derived from the engineering, manufacture and delivery of specialty mixing equipment and accessories. Indco receives customer product orders via phone call, email, internet or fax. The pricing of each standard product sold is listed in Indco’s print and web-based catalog. Customer specific products are priced by quote. A sales order acknowledgement is sent to every customer for every order to confirm pricing and the specifications of the products ordered. The revenue is recognized at a point in time when the product is shipped to the customer.
Life Sciences
Revenues from the Life Sciences segment are derived from the sale of high-quality monoclonal and polyclonal antibodies, diagnostic reagents and diagnostic kits and other immunoreagents for biomedical research and antibody manufacturing. Revenues are recognized when products are shipped and risk of loss is transferred to the carrier(s) used.
Income (loss) per common share
Basic net income (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding, excluding unvested restricted stock, during the period. Diluted net income (loss) per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options or warrants or the vesting of restricted stock units. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net income (loss) per share when their effect is anti-dilutive.
Stock-based compensation to employees
Equity classified share-based awards
The Company recognizes compensation expense for stock-based payments granted based on the grant-date fair value estimated in accordance with ASC Topic 718, “Compensation-Stock Compensation.” For employee stock-based awards, we calculate the fair value of the award on the date of grant using the Black-Scholes method for stock options and the quoted price of our common stock for restricted shares; the expense is recognized over the service period for awards expected to vest.
Stock-based compensation to non-employees
Liability classified share-based awards
The Company maintains other share unit compensation grants for shares of Indco, the Company’s majority-owned subsidiary, which vest over a period of up to three years following their grant. The shares contain certain put features where the Company is either required or expects to settle vested awards on a cash basis.
These awards are classified as liability awards, measured at fair value at the date of grant and re-measured at fair value at each reporting date up to and including the settlement date. The determination of the fair value of the share units under these plans is described in note 10. The fair value of the awards is expensed over the respective vesting period of the individual awards with recognition of a corresponding liability. Changes in fair value after vesting are recognized through compensation expense. Compensation expense reflects estimates of the number of instruments expected to vest. The impact of forfeitures and fair value revisions, if any, are recognized in earnings such that the cumulative expense reflects the revisions, with a corresponding adjustment to the settlement liability. Liability-classified share unit liabilities due within 12 months of the reporting date are presented in trade and other payables while settlements due beyond 12 months of the reporting date are presented in non-current liabilities.
Non-employee share-based awards
In prior periods up to September 30, 2019, the Company accounted for stock-based compensation to non-employees and consultants in accordance with the provisions of ASC 505-50, “Equity-Based Payments to Non-employees.” Measurement of share-based payment transactions with non-employees are based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of share-based payment transactions is determined at the earlier of performance commitment date or performance completion date. The Company believes that the fair value of the stock-based award is more reliably measurable than the fair value of the services received. The fair value of the granted stock-based awards is remeasured at each reporting date and expense is recognized over the vesting period of the award.
In June 2018, the FASB issued ASU No. 2018-07, Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting. The guidance was issued to simplify the accounting for share-based transactions by expanding the scope of Topic 718 from only being applicable to share-based payments to employees to also include share-based payment transactions for acquiring goods and services from nonemployees. As a result, nonemployee share-based transactions will be measured by estimating the fair value of the equity instruments at the grant date, taking into consideration the probability of satisfying performance conditions.

The Company adopted ASU 2018-07 on October 1, 2019. The adoption of the standard did not have a material impact on our financial statements for the six months ended March 31, 2020.
Mandatorily Redeemable Non-Controlling Interests
The non-controlling interests that are reflected as mandatorily redeemable non-controlling interests in the consolidated financial statements consist of non-controlling interests related to the Indco acquisition whose owners have certain redemption rights that allow them to require the Company to purchase the non-controlling interests of those owners upon certain events outside the control of the Company, including upon the death of the holder. The Company is required to purchase 20% of the 8.35% mandatorily redeemable non-controlling interest at the option of the holder beginning on the third anniversary of the date of the Indco acquisition, which was March 21, 2019. As of March 31, 2020, the holder did not exercise the redemption rights.
On the date the Company acquires the controlling interest in a business combination, the fair value of the non-controlling interest is recorded in the long-term liabilities section of the consolidated balance sheet under the caption “ Mandatorily redeemable non-controlling interest .” The mandatorily redeemable non-controlling interest is adjusted each reporting period, if required, to its then current redemption value, based on the predetermined formula defined in the respective agreement. The Company reflects any adjustment in the redemption value and any earnings attributable to the mandatorily redeemable non-controlling interest in its consolidated statements of operations by recording the adjustments and earnings to other income and expense in the caption “ change in fair value of mandatorily redeemable non-controlling interest .”
Note receivable
On March 2, 2018, the Company issued a convertible promissory note in the amount of $125 with a potential non- related party acquisition target. The note bears interest on the outstanding principal amount at a rate of 8% per annum, and both principal and interest is payable on the maturity date of April 24, 2020. The convertible note, at the election of the Company, can be converted into common stock of the acquisition target. As of March 31, 2020, and September 30, 2019, amounts outstanding including accrued interest were $142 and $139, respectively. As of March 31, 2020, the Company is no longer pursuing this potential acquisition target.
Income taxes
The Company uses the asset and liability method of accounting for income taxes in accordance with ASC Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the consolidated financial statements if such positions are more likely than not of being sustained.
Recent accounting pronouncements
Recently adopted accounting pronouncements
On October 1, 2019, the Company adopted ASU No. 2016-02, Leases (“ASC 842” or “ASU 2016-02”) issued by the FASB in February 2016 which was subsequently supplemented by clarifying guidance intended to improve financial reporting of leasing transactions. The new lease accounting guidance requires lessees to recognize lease liabilities and right-of-use assets on the balance sheet for all leases with initial terms longer than 12 months and provides enhanced disclosures on key information of leasing arrangements. The guidance allows companies to apply the requirements retrospectively, either to all prior periods presented or through a cumulative adjustment in the year of adoption.
The Company adopted the new standards effective October 1, 2019 using the modified retrospective transition method. The Company elected to use the package of practical expedients which allowed the Company to (i) not reassess whether an arrangement contains a lease, (ii) carry forward its lease classification as oper ating or capital leases and (iii) not reassess its previously-recorded initial direct costs. For all existing operating leases as of October 1, 2019, the Company recorded operating lease right of use asset of $1,043 and corresponding lease liabilities of $1,060, with an offset to other liabilities of $17 to eliminate deferred rent on the consolidated balance sheets.
Operating lease expense is recognized on a straight-line basis over the lease term. At each balance sheet date, operating lease liabilities represent the present value of the future minimum payments related to non-cancelable periods.
Leases with an initial term of 12 months or less (short-term leases) are not recognized in the balance sheet, and the related lease payments are recognized as incurred over the lease term.
All significant lease arrangements after October 1, 2019 are recognized as right-of-use assets and lease liabilities at lease commencement. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent its obligation to make lease payments arising from the lease. Right-of-use assets and liabilities are recognized at the commencement date based on the present value of the future lease payments using the Company’s incremental borrowing rate.
The adoption of the new lease accounting standard did not have a material impact on the Company’s results of operations or cash flows.
In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation , which expands the scope of Topic 718 to include all share-based payment transactions for acquiring goods and services from nonemployees. The amendments in this update are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, with early adoption permitted. The Company’s current share-based payment awards to      non-employees consist only of grants made to its non-employee directors as compensation solely relates to each individual’s role as a non-employee director. As such, in accordance with ASC 718, the Company accounts for these share-based payment awards to its non-employee directors in the same manner as share-based payment awards for its employees. The Company adopted this standard on October 1, 2019, and the amendments in this guidance had no material effect on either the accounting for its share-based payment awards to its non-employee directors, or the Company’s consolidated financial statements.
Recently issued accounting pronouncements not yet adopted
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement , which modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. This new accounting standard is effective for annual periods beginning after December 15, 2019. Early adoption is permitted. The Company is evaluating the effects that the adoption of this guidance will have on its disclosures.
In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment, to simplify the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. This new accounting standard is effective for annual periods beginning after December 15, 2019. Early adoption is permitted. The Company is evaluating the effects that the adoption of this guidance will have on its consolidated financial statements.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326), which replaces the incurred loss methodology previously employed to measure credit losses for most financial assets and requires the use of a forward-looking expected loss model. Current accounting delays the recognition of credit losses until it is probable a loss has been incurred, while the update will require financial assets to be measured at amortized costs less a reserve and equal to the net amount expected to be collected. This standard is effective for annual periods beginning after December 15, 2019, including interim periods within those fiscal years, with early adoption permitted. The Company is evaluating the effects that the adoption of this guidance will have on its consolidated financial statements.
Reclassifications
Prior year financial statement amounts are reclassified as necessary to conform to the current year presentation. These prior period reclassifications did not affect the Company’s net income, earnings per share, stockholders’ equity or working capital.
2.
ACQUISITIONS
The Company completed four business acquisitions in the fiscal year ended September 30, 2019, with an aggregate purchase price of $6,768, net of cash acquired. The Company recorded an aggregate $2,067 in goodwill and $2,165 in other identifiable intangibles. The results of operations of the acquired businesses are included in Janel’s consolidated results of operations since the date of each acquisition. Supplemental pro forma information has not been provided as the acquisitions did not have a material impact on Janel’s consolidated results of operations, individually or in the aggregate.
Honor Worldwide Logistics, LLC
Through its wholly-owned subsidiary, Janel Group, the Company acquired the membership interests of Honor on November 20, 2018 in a transaction pursuant to which Honor became a direct wholly-owned subsidiary of Janel Group and an indirect wholly-owned subsidiary of the Company. At closing, a subordinated promissory note in the aggregate amount of $456 was issued to a former member. The acquisition of Honor was funded with cash provided by normal operations along with a subordinated promissory note. Honor provides global logistics services with two U.S. locations and expands the domestic network of the Company’s Global Logistics Services segment. The results of operations for Honor are reflected in the Global Logistics Services reporting segment.
PhosphoSolutions
Through Aves, the Company completed a business combination whereby we acquired Phospho on September 6, 2019.  The aggregate purchase price for Phospho was $4,043, net of $13 of cash received.  At closing, $4,000 was paid in cash and $56 was recorded in accrued expenses as preliminary tax gross up due to former owners.  Phospho is a manufacturer and distributor of monoclonal and polyclonal antibodies, principally used in neuroscience research. Phospho was founded in 2001 and is headquartered in Aurora, Colorado. The results of operations for Phospho are reflected in the Life Sciences reporting segment.  As of March 31, 2020, the Company paid $172 in tax gross up consideration to former owners and recorded an additional $116 of goodwill related to the Phospho acquistion.
Other Acquisitions
On October 17, 2018, we completed a business combination whereby we acquired substantially all of the assets and certain liabilities of a global logistics services provider with one U.S. location. On July 1, 2019, we acquired the membership interests of a life sciences company to expand our product offerings in Life Sciences. These acquisitions were funded with cash provided by normal operations. The results of operations for these acquisitions are reported in our Global Logistics Services and Life Sciences segments. The aggregate purchase price for these acquisitions was $430. At closing, $50 was recorded in accrued expenses as a preliminary earnout consideration.
3.
INVENTORY
Inventories consisted of the following:
March 31,
2020
September 30,
2019
Finished Goods
$
2,627
$
2,988
Work-in-Process
326
461
Raw Materials
1,251
946
Less - Reserve for Inventory Valuation
(26
)
(24
)
Inventory Net
$
$ 4,178
$
4,371

4.
PROPERTY AND EQUIPMENT
A summary of property and equipment and the estimated lives used in the computation of depreciation and amortization is as follows:
March 31,
2020
September 30,
2019
Life
Building and Improvements
$
2,553
$
2,577
15-30 Years
Land and Improvements
869
835
Indefinite
Furniture & Fixtures
285
218
3-7 Years
Computer Equipment
299
465
3-5 Years
Machinery & Equipment
1,151
973
3-15 Years
Leasehold Improvements
181
181
Shorter of Lease Term or Asset Life
5,338
5,249
Less: Accumulated Depreciation
(1,346
)
(1,295
)
$
3,992
$
3,954

Depreciation expense for the six months ended March 31, 2020 and 2019 was $92 and $152, respectively.
5.
INTANGIBLE ASSETS
A summary of intangible assets and the estimated useful lives used in the computation of amortization is as follows:
March 31,
2020
September 30,
2019
Life
Customer Relationships
$
13,762
$
13,762
15-20 Years
Trademarks / Names
2,251
2,251
20 Years
Other
978
978
2-5 Years
16,991
16,991
Less: Accumulated Amortization
(3,879
)
(3,393
)
$
13,112
$
13,598

Amortization expense for the six months ended March 31, 2020 and 2019 was $486 and $444, respectively.
6.
GOODWILL
The Company’s goodwill carrying amounts relate to the acquisitions in the Global Logistics Services, Manufacturing and Life Sciences businesses.  As of March 31, 2020, the Company paid $172 in tax gross up consideration to former owners and recorded an additional $116 of goodwill related to the Phospho acquistion.
The composition of the goodwill balance at March 31, 2020 and September 30, 2019 was as follows:

March 31,
2020
September 30,
2019
Global Logistics Services
$
5,655
$
5,655
Manufacturing
5,046
5,046
Life Sciences
2,940
2,824
$
13,641
$
13,525

7.
NOTES PAYABLE - BANKS
(A)
Santander Bank Facility
On October 17, 2017, the Janel Group subsidiaries (collectively the “Janel Group Borrowers”), with the Company as a guarantor, entered into a Loan and Security Agreement (the “Santander Loan Agreement”) with Santander Bank, N.A. (“Santander”) with respect to a revolving line of credit facility (the “Santander Facility”).  As amended in March 2018, November 2018 and March 2020, the Santander Facility currently provides that the Janel Group Borrowers can borrow up to $17,000 limited to 85% of the Janel Group Borrowers’ aggregate outstanding eligible accounts receivable, subject to adjustment as set forth in the Santander Loan Agreement. Interest accrues on the Santander Facility at an annual rate equal to, at the Janel Group Borrowers’ option, prime plus 0.50%, or LIBOR (30, 60 or 90 day) plus 2.25% subject to a LIBOR floor of 75 basis points. The Janel Group Borrowers’ obligations under the Santander Facility are secured by all of the assets of the Janel Group Borrowers, while the Santander Loan Agreement contains customary terms and covenants. The Santander Facility matures on October 17, 2022, unless earlier terminated or renewed.  As a result of its terms, the Santander Facility is classified as a current liability on the consolidated balance sheet.
At March 31, 2020, outstanding borrowings under the Santander Facility were $7,533, representing 82.33% of the available amount thereunder, and interest was accruing at an effective interest rate of 3.26%. The Janel Group Borrowers were in compliance with the covenants defined in the Santander Loan Agreement at March 31, 2020 and September 30, 2019.
(B)
First Merchants Bank Credit Facility
On March 21, 2016, as amended in August 2019, Indco entered into a Credit Agreement (the “First Merchants Credit Agreement”) with First Merchants Bank with respect to a $5,500 term loan and $1,000 (limited to the borrowing base and reserves) revolving loan (together, the “First Merchants Facility”). Interest accrues on the term loan at an annual rate equal to the one-month LIBOR plus either 2.75% (if Indco’s total funded debt to EBITDA ratio is less than 2:1), or 3.5% (if Indco’s total funded debt to EBITDA ratio is greater than or equal to 2:1). Interest accrues on the revolving loan at an annual rate equal to the one-month LIBOR plus 2.75%. Indco’s obligations under the First Merchants Facility are secured by all of Indco’s assets and are guaranteed by the Company, and the Company’s guarantee of Indco’s obligations is secured by a pledge of the Company’s Indco shares. The First Merchants Credit Agreement contains customary terms and covenants. The First Merchants Facility will expire on August 30, 2024 (subject to earlier termination as provided in the Credit Agreement) unless renewed.
As of March 31, 2020, there were no outstanding borrowings under the revolving loan and $4,931 of borrowings under the term loan, with interest accruing on the term loan at an effective interest rate of 5.08%.
The Company was in compliance with the covenants defined in the First Merchants Credit Agreement at March 31, 2020 and September 30, 2019.
March 31,
2020
September 30,
2019
Long Term Debt *
$
4,931
$
5,455
Less Current Portion
(786
)
(786
)
$
4,145
$
4,669

*
Note: Long Term Debt is due in monthly installments of $71 plus monthly interest, at LIBOR plus 3.75% to 4.75% per annum. The note is collateralized by all of Indco’s assets and guaranteed by Janel.
(C)
First Northern Bank of Dixon
On June 21, 2018, AB Merger Sub, Inc., a wholly-owned, indirect subsidiary of the Company, entered into a Business Loan Agreement (the “First Northern Loan Agreement”) with First Northern Bank of Dixon (“First Northern”), with respect to a $2,025 First Northern Term Loan (the “First Northern Term Loan”). The proceeds of the First Northern Term Loan were used to fund a portion of the merger consideration to acquire Antibodies.  Interest was to accrue on the First Northern Term Loan at an annual rate based on the five-year Treasury constant maturity (index) plus 2.50% (margin) for years one through five then adjusted and fixed for years six through ten using the same index and margin. The borrower’s and the Company’s obligations to First Northern under the First Northern Loan Agreement are secured by certain real property owned by Antibodies as of the closing of the Antibodies merger. The First Northern Loan Agreement contains customary terms and covenants and matures on June 14, 2028 (subject to earlier termination).
On November 18, 2019, Antibodies modified and refinanced its existing credit facilities with First Northern Bank. The existing First Northern Term Loan was increased to $2,235, the initial interest rate decreased to 4.18%, and the maturity date was extended to November 14, 2029, with all other terms, covenants and conditions substantially unchanged. The existing revolving credit facility was expanded to $500, the interest rate decreased to 6.0%, and the maturity date was extended to October 1, 2020, with all other terms, covenants and conditions substantially unchanged. Additionally, Antibodies entered into a new business loan agreement (“Solar Loan”) which provided for a $125 term loan in connection with a potential expansion of solar generation capacity on the Antibodies property. The initial interest rate on the facility is 4.43%, subject to adjustment in five years.
As of March 31, 2020, there were no outstanding borrowings under the revolving credit facility and $2,217 of borrowings under the term loan.
March 31,
2020
September 30,
2019
Long Term Debt *
$
2,217
$
1,975
Less Current Portion
(52
)
(42
)
$
$2,165
$
1,933

*
Note: Long Term Debt is due in monthly principal and interest installments of $12 plus monthly interest, at an effective interest rate of 4.18% as of March 31, 2020 and 5.28% as of September, 2019, per annum. The note is collateralized by real property owned by Antibodies and guaranteed by Janel.
The Company was in compliance with the covenants defined in the First Northern Loan Agreement at March 31, 2020 and September 30, 2019.
8.
SUBORDINATED PROMISSORY NOTES
On June 22, 2018, in connection with the Antibodies acquisition, AB HoldCo, Inc. (“AB HoldCo”), a wholly-owned subsidiary of the Company, entered into two subordinated promissory notes (“AB HoldCo Subordinated Promissory Notes”) with certain former shareholders of Antibodies. As the result of the merger of AB HoldCo into Antibodies, Antibodies became the obligor under the AB HoldCo Subordinated Promissory Notes.  Both of the AB HoldCo Subordinated Promissory Notes are guaranteed by the Company and are subordinate to the terms of any credit agreement, loan agreement, indenture, promissory note, guaranty or other debt instrument pursuant to which the obligor  or any affiliate of the obligor  incurs, borrows, extends, guarantees, renews or refinances any indebtedness for borrowed money or other extensions of credit with any federal or state bank or other institutional lender and are unsecured. Each of the AB HoldCo Subordinated Promissory Notes has a 4% annual interest rate payable in arrears on the last business day of each calendar quarter, commencing on September 30, 2018, and the full outstanding principal balance and accrued, unpaid interest is due on June 22, 2021. Both notes are subject to prepayment in whole or in part, without premium or penalty, of the outstanding principal amount of the notes, together with all accrued interest on such principal amount up to the date of prepayment.  Any prepayment shall be applied first to accrued but unpaid interest, and then to outstanding principal. As of March 31, 2020, and September 30, 2019, amounts outstanding under the two AB HoldCo Subordinated Promissory Notes was $344 and is included in the l ong term portion of subordinated promissory notes.
On November 20, 2018, in connection with the Honor acquisition, Janel Group, a wholly-owned subsidiary of the Company, entered into a subordinated promissory note (“Janel Group Subordinated Promissory Note”) with a former owner of Honor. The Janel Group Subordinated Promissory Note is guaranteed by the Company. The Janel Group Subordinated Promissory Note is subordinate to and junior in right of payment for principal interest premiums and other amounts payable to the Santander Bank Facility and the First Merchants Bank Credit Facility. The Janel Group Subordinated Promissory Note, has a 6.75% annual interest rate, payable in twelve equal consecutive quarterly installments of principal and interest, on the last day of January, April, July and October beginning in January 2019, and shall be due and payable each in the amount of $42. The outstanding principal and accrued and unpaid interest are payable in a single payment on the three-year anniversary date of November 20, 2021. The note is subject to prepayment in whole or in part, without premium or penalty, of the outstanding principal amount of the notes, together with all accrued but unpaid interest on such principal amount up to the date of prepayment.  As of March 31, 2020, and September 30, 2019, the amounts outstanding under the Janel Group Subordinated Promissory Note was $276 and $349, respectively.

March 31,
2020
September 30,
2019
Long term portion of subordinated promissory notes
$
121
$
197
Current portion of subordinated promissory note
155
152
$
276
$
349

9.
STOCKHOLDERS’ EQUITY
Janel is authorized to issue 4,500,000 shares of common stock, par value $0.001. In addition, the Company is authorized to issue 100,000 shares of preferred stock, par value $0.001. The preferred stock is issuable in series with such voting rights, if any, designations, powers, preferences and other rights and such qualifications, limitations and restrictions as may be determined by the Company’s board of directors or a duly authorized committee thereof, without stockholder approval. The board of directors may fix the number of shares constituting each series and increase or decrease the number of shares of any series.
(A)
Preferred Stock
Series B Convertible Preferred Stock
Shares of the Company’s Series B Convertible Preferred Stock (the “Series B Stock”) are convertible into shares of the Company’s $0.001 par value common stock at any time on a one-share (of Series B Stock) for ten-shares (of common stock) basis. On September 6, 2019, a holder of the Series B Stock converted 640 shares of Series B Stock into 6,400 shares of the Company’s Common Stock.
Series C Cumulative Preferred Stock
Shares of the Company’s Series C Cumulative Preferred Stock (the “Series C Stock”) are entitled to receive annual dividends at a rate of 5% per annum of the original issuance price of $10, when and if declared by the Company’s board of directors, with such rate increased by 1% annually beginning on January 1, 2019.  Such rate is to increase on each January 1 thereafter for four years to a maximum rate of 9%. The dividend rate of the Series C Stock as of March 31, 2020 was 7%. In the event of liquidation, holders of the Series C Stock shall be paid an amount equal to the original issuance price, plus any accrued but unpaid dividends thereon. Shares of the Series C Stock may be redeemed by the Company at any time upon notice and payment of the original issuance price, plus any accrued but unpaid dividends thereon. The liquidation value of the Series C Stock was $12,867 as of March 31, 2020.
For the six months ended March 31, 2020, the Company declared dividends on the Series C Stock of $326. As of March 31, 2020, the Company had accrued dividends of $1,366.
(B)
Equity Incentive Plan
On May 12, 2017, the Company adopted the 2017 Equity Incentive Plan which was amended on May 8, 2018 (as amended, the “2017 Plan”).  Under the 2017 Plan, non-statutory stock options, restricted stock awards and stock appreciation rights with respect to shares of the Company’s common stock may be granted to directors, officers, employees of and consultants to the Company. Participants and all terms of any awards under the Plan are at the discretion of the Company’s Compensation Committee of the board of directors.
10.
STOCK-BASED COMPENSATION
On October 30, 2013, the board of directors of the Company adopted the Company’s 2013 Non-Qualified Stock Option Plan (the “2013 Option Plan”) providing for options to purchase up to 100,000 shares of the Company’s common stock for issuance to directors, officers, employees of and consultants to the Company and its subsidiaries.
Total stock-based compensation for the six months ended March 31, 2020 and 2019 amounted to $149 and $236, respectively, and was included in selling, general and administrative expense in the Company’s statements of operations.
(A)
Stock Options
The Company uses the Black-Scholes option pricing model to estimate the fair value of our share-based awards. In applying this model, we use the following assumptions:

•
Risk-free interest rate - We determine the risk-free interest rate by using a weighted average assumption equivalent to the expected term based on the U.S. Treasury constant maturity rate.

•
Expected term - We estimate the expected term of our options on the average of the vesting date and term of the option.

•
Expected volatility - We estimate expected volatility using daily historical trading data of a peer group.

•
Dividend yield - We have never paid dividends on our common stock and currently have no plans to do so; therefore, no dividend yield is applied.
The fair values of our employee option awards were estimated using the assumptions below, which yielded the following weighted average grant date fair values for the periods presented:
Six Months Ended
March 31,
2020
Risk-free Interest Rate
1.59%

Expected Option Term in Years
5.5-6.5
Expected Volatility
101.2% - 101.7%

Dividend Yield
0%

Weighted Average Grant Date Fair Value

$6.97 - $7.33

Options for Employees
Number of
Options
Weighted
Average Exercise
Price
Weighted
Average
Remaining
Contractual
Term (in years)
Aggregate
Intrinsic Value
(in thousands)
Outstanding Balance at September 30, 2019
110,837
$
5.05
5.98
$
438.06
Granted
7,500
$
9.00
9.75
$
—
Exercised
(3,841
)
$
8.17
—
$
—
Outstanding Balance at March 31, 2020
114,496
$
5.21
5.67
$
290.88
Exercisable on March 31, 2020
96,792
$
4.62
5.15
$
290.88

The aggregate intrinsic value in the above table was calculated as the difference between the closing price of the Company’s common stock at March 31, 2020 of $7.50 per share and the exercise price of the stock options that had strike prices below such closing price.
As of March 31, 2020, there was approximately $51 of total unrecognized compensation expense related to the unvested employee stock options which is expected to be recognized over a weighted average period of less than one year.
Options for Non-Employees
There were no non-employee options awarded during the six-month period ended March 31, 2020. During the six-month period ended March 31, 2020, 15,000 non-employee options were forfeited.
Number of
Options
Weighted
Average Exercise
Price
Weighted
Average
Remaining
Contractual
Term (in years)
Aggregate
Intrinsic Value
(in thousands)
Outstanding Balance at September 30, 2019
51,053
$
7.58
7.80
$
72.68
Forfeited
(15,000
)
$
8.04
—
$
—
Outstanding Balance at March 31, 2020
36,053
$
7.38
7.26
$
20.40
Exercisable on March 31, 2020
6,053
$
4.13
6.50
$
20.40

The aggregate intrinsic value in the above table was calculated as the difference between the closing price of our common stock at March 31, 2020, of $7.50 per share and the exercise price of the stock options that had strike prices below such closing price.
As of March 31, 2020, there was approximately $32 of total unrecognized compensation expense related to the unvested stock options, which is expected to be recognized over a weighted average period of less than one year.
Liability classified share-based awards
Additionally, during the six months ended March 31, 2020, 6,880 options were granted with respect to Indco’s common stock. The Company uses the Black-Scholes option pricing model to estimate the fair value of Indco’s share-based awards. In applying this model, the Company used the following assumptions:
Six Months Ended
March 31,
2020
Risk-free Interest Rate
1.59%

Expected Option Term in Years
5.5 - 6.5
Expected Volatility
101.2% - 101.7%

Dividend Yield
0%

Weighted Average Grant Date Fair Value

$8.59 - $9.03

Number of
Options
Weighted
Average Exercise
Price
Weighted
Average
Remaining
Contractual
Term (in years)
Aggregate
Intrinsic Value
(in thousands)
Outstanding Balance at September 30, 2019
32,133
$
8.85
7.34
$
85.45
Granted
6,880
$
11.08
9.75
$
—
Outstanding Balance at March 31, 2020
39,013
$
9.24
7.31
$
85.45
Exercisable on March 31, 2020
23,343
$
7.98
6.49
$
85.45

The aggregate intrinsic value in the above table was calculated as the difference between the valuation price of Indco’s common stock at March 31, 2020 of $11.08 per share and the exercise price of the stock options that had strike prices below such closing price.
The liability classified awards were measured at fair value at each reporting date until the final measurement date, which was the date of completion of services required to earn the option. The accrued compensation cost related to these options was approximately $302 and $172 as of March 31, 2020 and September 30, 2019, respectively, and is included in other liabilities in the consolidated financial statement.  The cost associated with the options issued on each grant date is being recognized ratably over the period of service required to earn each tranche of options.
Upon vesting, the options continue to be accounted for as a liability in accordance with ASC 480-10-25-8 and are measured in accordance with ASC 480-10-35 at every reporting period until the options are settled. Changes in the fair value of the vested options are recognized in earnings in the consolidated financial statements.
The options are classified as liabilities, and the underlying shares of Indco’s common stock also contain put options which result in their classification as mandatorily redeemable securities. While their redemption does not occur on a fixed date, there is an unconditional obligation for the Company to repurchase the shares upon death, which is certain to occur at some point in time.
As of March 31, 2020, there was approximately $66 of total unrecognized compensation expense related to the unvested Indco stock options. This expense is expected to be recognized over a weighted average period of less than one year.
(B)
Restricted Stock
During the six months ended March 31, 2020, there were no shares of restricted stock granted. Under the 2017 Plan, each grant of restricted stock vests over a three-year period, and the cost to the recipient is zero. Restricted stock compensation expense, which is a non-cash item, is being recognized in the Company’s financial statements over the vesting period of each restricted stock grant.
The following table summarizes the status of our employee unvested restricted stock under the 2017 Plan for the six months ended March 31, 2020:
Restricted Stock
(in thousands)
Weighted Average
Grant Date Fair Value
Weighted Average
Remaining
Contractual Term
(in years)
Unvested at September 30, 2019
5,000
$
8.01
0.61
Vested
—
$
—
—
Unvested at March 31, 2020
5,000
$
8.01
0.11

As of March 31, 2020, there was approximately $2 of total unrecognized compensation cost related to unvested employee restricted stock. The cost is expected to be recognized over a weighted-average period of approximately 0.11 years.
The following table summarizes the status of our non-employee unvested restricted stock under the 2017 Plan for the six months ended March 31, 2020:
Restricted Stock
(in thousands)
Weighted Average
Grant Date Fair Value
Weighted Average
Remaining
Contractual Term
(in years)
Unvested at September 30, 2019
26,667
$
8.04
0.88
Vested
—
$
—
—
Unvested at March 31, 2020
26,667
$
8.04
0.38

As of March 31, 2020, there was approximately $30 of unrecognized compensation cost related to non-employee unvested restricted stock. The cost is expected to be recognized over a weighted-average period of approximately 0.38 years.
As of March 31, 2020, included in accrued expenses and other current liabilities was $159 which represents 18,333 shares of restricted stock that vested but were not issued.
11.
INCOME PER COMMON SHARE
The following table provides a reconciliation of the basic and diluted income (loss) per share (“EPS”) computations for the three and six months ended March 31, 2020 and 2019 (in thousands, except share and per share data):
For the Three Months Ended
March 31,
For the Six Months Ended
March 31,
2020
2019
2020
2019
Income:
Net income (loss)
$
(937
)
$
175
$
(1,057
)
$
719
Preferred stock dividends
(175
)
(148
)
(326
)
(270
)
Net Income (loss) available to common stockholders
$
(1,112
)
$
27
$
(1,383
)
$
449
Common Shares:
Basic - weighted average common shares
865,985
847,784
865,630
847,621
Effect of dilutive securities:
Stock options
—
51,097
—
54,644
Restricted stock
—
20,369
—
19,162
Convertible preferred stock
—
12,710
—
12,710
Diluted - weighted average common stock
$
865,985
$
931,960
$
865,630
$
934,137
Income per Common Share:
Basic -
Net income (loss)
$
(1.08
)
$
0.21
$
(1.22
)
$
0.85
Preferred stock dividends
(0.21
)
(0.17
)
(0.38
)
(0.32
)
Net Income (loss) available to common stockholders
$
(1.29
)
$
0.04
$
(1.60
)
$
0.53
Diluted -
Net income (loss)
$
(1.08
)
$
0.18
$
(1.22
)
$
0.77
Preferred stock dividends
(0.21
)
(0.15
)
(0.38
)
(0.29
)
Net income (loss) available to common stockholders
$
(1.29
)
$
0.03
$
(1.60
)
$
0.48

The computation for the diluted number of shares excludes unvested restricted stock, unexercised stock options and unexercised warrants that are anti-dilutive. There were no anti-dilutive shares for the six-month periods ended March 31, 2020.
Potentially dilutive securities as of March 31, 2020 and 2019 were as follows:
March 31,
2020
2019
Employee Stock Options
114,496
118,798
Non-employee Stock Options
36,053
51,053
Employee Restricted Stock
5,000
5,000
Non-employee Restricted Stock
26,667
26,667
Convertible Preferred Stock
6,310
12,710
188,526
214,228

12.
INCOME TAXES
The Company’s estimated fiscal 2020 and 2019 blended U.S. federal statutory corporate income tax rate of 10.1% and 25.2%, respectively, were applied in the computation of the Company’s income tax provision for the six months ended March 31, 2020 and 2019.

The reconciliation of income tax computed at the Federal statutory rate to the benefit (provision) for income taxes for the six months ended March 31, 2020 is as follows:

March 31,
2020
March 31,
2019
Federal taxes at statutory rates
$
247
$
(204
)
Permanent differences
(28
)
(13
)
Other
(63
)
-
State and local taxes
(37
)
(36
)
Income tax benefit (expense)
$
119
$
(253
)

13.
BUSINESS SEGMENT INFORMATION
As discussed above in note 1, the Company operates in three reportable segments: 1) Global Logistics Services, 2) Manufacturing and 3) Life Sciences, supported by a corporate group which conducts activities that are non-segment specific. The following tables present selected financial information about the Company’s reportable segments for the three and six months ended March 31, 2020:
For the three months ended
March 31, 2020
Consolidated
Global Logistics
Services
Manufacturing
Life Sciences
Corporate
Revenue
$
19,121
$
15,328
$
2,056
$
1,737
$
—
Forwarding expenses and cost of revenues
13,125
11,615
908
602
—
Gross profit
5,996
3,713
1,148
1,135
—
Selling, general and administrative
6,584
3,952
701
1,071
860
Amortization of intangible assets
243
—
—
—
243
Operating (loss) income
(831
)
(239
)
447
64
(1,103
)
Interest expense (income) net
141
54
66
24
(3
)
Identifiable assets
55,868
14,012
2,425
9,650
26,781
Capital expenditures
34
17
—
17
—

For the six months ended
March 31, 2020
Consolidated
Global Logistics
Services
Manufacturing
Life Sciences
Corporate
Revenue
$
38,942
$
31,407
$
3,926
$
3,609
$
—
Forwarding expenses and cost of revenues
26,659
23,702
1,753
1,204
—
Gross profit
12,283
7,705
2,173
2,405
—
Selling, general and administrative
12,669
7,590
1,383
2,051
1,645
Amortization of intangible assets
486
—
—
—
486
Operating (loss) income
(872
)
115
790
354
(2,131
)
Interest expense (income) net
304
120
138
51
(5
)
Identifiable assets
52,868
14,012
2,425
9,650
26,781
Capital expenditures
131
64
23
44
—

The following tables present selected financial information about the Company’s reportable segments for the three and six months ended March 31, 2019:
For the three months ended
March 31, 2019
Consolidated
Global Logistics
Services
Manufacturing
Life Sciences
Corporate
Revenue
$
20,969
$
16,865
$
2,452
$
1,652
$
—
Forwarding expenses and cost of revenues
14,599
12,957
1,077
565
—
Gross profit
6,370
3,908
1,375
1,087
—
Selling, general and administrative
5,692
3,468
759
724
741
Amortization of intangible assets
236
—
—
—
236
Operating income (loss)
442
440
616
363
(977
)
Interest expense (income) net
198
127
36
37
(2
)
Identifiable assets
52,868
14,012
2,425
9,650
26,781
Capital expenditures
71
2

—
69
—

For the six months ended
March 31, 2019
Consolidated
Global Logistics
Services
Manufacturing
Life Sciences
Corporate
Revenue
$
43,296
$
35,670
$
4,533
$
3,093
$
—
Forwarding expenses and cost of revenues
30,439
27,375
2,010
1,054
—
Gross profit
12,857
8,295
2,523
2,039
—
Selling, general and administrative
11,081
6,828
1,467
1,431
1,355
Amortization of intangible assets
444
—
—
—
444
Operating income (loss)
1,332
1,467
1,056
608
(1,799
)
Interest expense (income) net
360
225
76
64
(5
)
Identifiable assets
55,348
20,825
2,418
6,672
25,433
Capital expenditures
253
16
41
196
—

14.
RISKS AND UNCERTAINTIES
(A)
Currency Risks
The nature of Janel’s operations requires it to deal with currencies other than the U.S. Dollar. As a result, the Company is exposed to the inherent risks of international currency markets and governmental interference. A number of countries where Janel maintains offices or agent relationships have currency control regulations. The Company attempts to compensate for these exposures by accelerating international currency settlements among those agents.
(B)
Concentration of Credit Risk
The Company’s assets that are exposed to concentrations of credit risk consist primarily of cash and receivables from customers. The Company places its cash with financial institutions that have high credit ratings. The receivables from clients are spread over many customers. The Company maintains an allowance for uncollectible accounts receivable based on expected collectability and performs ongoing credit evaluations of its customers’ financial condition. We have experienced heightened customer credit risk as a result of the negative impact to customers’ financial condition, employment levels and consumer confidence arising from economic disruptions related to the COVID-19 pandemic, and expect that our risk in this area will remain high as long as the disruptions persist.
(C)
Legal Proceedings
Janel is occasionally subject to claims and lawsuits which typically arise in the normal course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe that the outcome of any of these legal matters will have a material adverse effect on the Company’s business, results of operations, financial condition or cash flows.
In December 2017, Janel Group received a Notice of Copyright Infringement letter from counsel for Warren Communications News, Inc. (“Warren”), the publisher of the International Trade Today (“ITT”) newsletter. The letter alleges that Janel Group infringed upon Warren’s registered copyrights in its ITT newsletter (the “Warren Matter”). As of March 31, 2020, the Company had a liability for settlement costs related to the Warren Matter, which is included in accrued expenses and other current liabilities. On May 11, 2020, the parties reached a settlement agreement and release to resolve any and all concerns between the parties, voluntarily and without admission of copyright infringement.
(D)
COVID-19
In March 2020, the World Health Organization declared the outbreak of a novel coronavirus (COVID-19) as a pandemic. As a result, public health measures have been taken by federal, state and local governments to minimize exposure to and contain the virus. Measures intended to reduce the spread of COVID-19, such as quarantines, travel restrictions and other governmental restrictions such as social distancing protocols, have has, and are likely to continue to have, an adverse impact on economic activity, including with respect to business closures, increasing unemployment levels and financial market instability. The extent or duration of the disruption on global, national, and local economies cannot be reasonably estimated at this time. However, should the pandemic and its economic impact continue for an extended period, the Company’s future business operations, including its results of operations, cash flows and financial position could be significantly affected.
15.
COMMITMENTS AND CONTINGENCIES
On February 4, 2020, Indco, Inc., a majority-owned subsidiary of the Company, entered into a Purchase and Sale Agreement with 4040 Earnings Way, LLC (“Seller”) to acquire from Seller the land and building which serves as the Indco office and manufacturing facility in New Albany, Indiana, for a purchase price of $845. Indco anticipates that the purchase price will be financed with cash from operations and a loan of up to $700 from First Merchants Bank secured by the subject property. Closing is expected to occur during the third quarter of fiscal 2020, ending June 30, 2020.
16.
LEASES
The Company has operating leases for office and warehouse space in all districts where it conducts business. As of March 31, 2020, the remaining terms of the Company’s operating leases were between one and 58 months and certain lease agreements contain provisions for future rent increases. Payments due under the lease contracts include the minimum lease payments that the Company is obligated to make under the non-cancelable initial terms of the leases as the renewal terms are at the Company’s option and the Company is not reasonably certain to exercise those renewal options at lease commencement..
The components of lease cost for the six-month period ended March 31, 2020 are as follows:
Six Months Ended
March 31,
2020
Operating lease cost
$
353
Short-term lease cost
68
Total lease cost
$
421

Rent expense for the six-month period March 31, 2019 was $372

Operating lease right of use asset, current portion of operating lease liabilities and long-term operating lease liabilities reported in the consolidated balance sheets for operating leases as of March 31, 2020 were $1,599, $479 and $1,142, respectively.

During the three months ended March 31, 2020, the Company entered into a new operating lease and recorded an addition $857 in operating lease right of use asset of and corresponding lease liabilities.
As of March 31, 2020, the weighted-average remaining lease term and the weighted-average discount rate related to the Company’s operating leases were 3.9 years and 6.58%, respectively. Cash paid for amounts included in the measurement of operating lease obligations were $410 for the six months ended March 31, 2020.
Future minimum lease payments under non-cancelable operating leases as of March 31, 2020 are as follows:
2020
$
493
2021
469
2022
414
2023
241
2024
221
Total undiscounted lease payments
1,838
Less: Imputed interest
(217
)
Total lease obligations
$
1,621

17.
SUBSEQUENT EVENTS
CARES Act Loan

The Coronavirus Aid, Relief and Economic Security Act, Section 7(a)(36) of the Small Business Act (the “CARES Act”), which was signed into law in March 2020, established the Paycheck Protection Program (the “PPP”). The PPP authorizes up to $349 billion in forgivable loans to small businesses. Loan amounts are forgiven to the extent proceeds are used to cover documented payroll, mortgage interest, rent and utility costs over an eight-week measurement period following loan funding. Loans have a maturity of two years and bear interest at a rate of 1.00% per annum.  Prepayments may be made at any time prior to maturity without penalty.

On April 19, 2020, the Company entered into a Loan Agreement (the “Loan Agreement”) with Santander and executed a U.S. Small Business Administration Note (the “Note”) pursuant to which the Company borrowed $2,726 (the “Loan”) from Santander pursuant to the PPP under the CARES Act.

The Loan matures on April 19, 2022 and bears interest at a rate of 1.00% per annum, payable monthly commencing on November 19, 2020. The Note may be prepaid by Janel at any time prior to maturity with no prepayment penalties. Funds from the Loan may only be used for payroll costs, costs used to continue group health care benefits, mortgage payments, rent and utilities (collectively, “Qualifying Expenses”).  Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are used for Qualifying Expenses as described in the CARES Act. The Company's participation in the PPP subsequent to quarter end should allow the Company to avoid significant staff reductions in the near term.

As discussed in note 14 (C) above, the Company received a letter in December 2017 from legal counsel representing Warren in which Warren made certain allegations against the Company of copyright infringement concerning an electronic newsletter by Warren.  On May 11, 2020, the parties reached a settlement agreement and release to resolve any and all concerns between the parties, voluntarily and without admission of copyright infringement. As of March 31, 2020, the Company had a liability for settlement costs related to the Warren Matter, which is included in accrued expenses and other current liabilities.

ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis should be read in conjunction with our unaudited interim consolidated financial statements and related notes thereto as of and for the six months ended March 31, 2020, which have been prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). Amounts presented in this section are in thousands, except share and per share data.

As used throughout this Report, “we,” “us”, “our,” “Janel,” “the Company,” “Registrant” and similar words refer to Janel Corporation and its Subsidiaries.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (the “Report”) contains certain statements that are, or may deemed to be, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and that reflect management’s current expectations with respect to our operations, performance, financial condition, and other developments. These forward-looking statements may generally be identified by the use of the words “may,” “will,” “intends,” “plans,” projects,” “believes,” “should,” “expects,” “predicts,” “anticipates,” “estimates,” and similar expressions or the negative of these terms or other comparable terminology. These statements are necessarily estimates reflecting management’s best judgment based upon current information and involve a number of risks, uncertainties and assumptions. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made, and readers are advised that various factors, including, but not limited to, those set forth elsewhere in this Report, could affect our financial performance and could cause our actual results for future periods to differ materially from those anticipated or projected. While it is impossible to identify all such factors, such factors include, but are not limited to, the impact of the coronavirus (“COVID-19”) pandemic and related economic effects; our strategy of expanding our business through acquisitions of other businesses; the risk that we may fail to realize the expected benefits or strategic objectives of any acquisition, or that we spend resources exploring acquisitions that are not consummated; litigation; indemnification claims and other unforeseen claims and liabilities that may arise from an acquisition; economic and other conditions in the markets in which we operate; the risk that we may not have sufficient working capital to continue operations; instability in the financial markets; the material weaknesses identified in our internal control over financial reporting; our dependence on key employees; competition from parties who sell their businesses to us and from professionals who cease working for us; terrorist attacks and other acts of violence or war; security breaches or cybersecurity attacks; competition faced by our global logistics services freight carriers with greater financial resources and from companies that operate in areas in which we plan to expand; our dependence on the availability of cargo space from third parties; recessions and other economic developments that reduce freight volumes; other events affecting the volume of international trade and international operations; risks arising from our global logistics services business’ ability to manage staffing needs; competition faced in the freight forwarding, freight brokerage, logistics and supply chain management industry; industry consolidation and our ability to gain sufficient market presence with respect to our global logistics services business; risks arising from our ability to comply with governmental permit and licensing requirements or statutory and regulatory requirements; seasonal trends; competition faced by our manufacturing (Indco) business from competitors with greater financial resources; Indco’s dependence on individual purchase orders to generate revenue; any decrease in the availability, or increase in the cost, of raw materials used by Indco; Indco’s ability to obtain and retain skilled technical personnel; risks associated with product liability claims due to alleged defects in Indco’s products; risks arising from the environmental, health and safety regulations applicable to Indco; the reliance of our Indco and life sciences businesses on a single location to manufacture their products; the ability of our life sciences business to compete effectively; the ability of our life sciences business to introduce new products in a timely manner; product or other liabilities associated with the manufacture and sale of new products and services; changes in governmental regulations applicable to our life sciences business; the ability of our life sciences business to continually produce products that meet high quality standards such as purity, reproducibility and/or absence of cross-reactivity; the controlling influence exerted by our officers and directors and one of our stockholders; our inability to issue dividends in the foreseeable future; and risks related to ownership of our common stock, including volatility and the lack of a guaranteed continued public trading market for our common stock. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those projected.  You should not place undue reliance on any of our forward-looking statements which speak only as of the date they are made.  We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed discussion of these factors, see our periodic reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2019.
COVID-19

The outbreak of COVID-19 has had a significant impact on global trade and our business. In late January 2020, China implemented extensive business shutdowns and work restrictions to control the outbreak, which resulted in a steep drop in exports from China. Those shutdowns and restrictions in China started to ease in March 2020, and export volumes from China increased throughout the month. The spread of COVID-19 to other parts of the world, and the strong actions taken by many countries to reduce exposure to the virus, however, have led to a sharp decrease in global economic activity during the second quarter of fiscal 2020 and a second steep drop in global import and export trade volumes, which has materially impacted our Global Logistics Services business. Specifically, in the three months ended March 31, 2020, we experienced a decrease of 9.1% in our Global Logistics Services segment revenues as a result of the global trade slowdown due to the COVID- 19 pandemic. We also experienced a significant slowdown in organic growth in both our Manufacturing and Life Sciences segments due to a slowdown in orders and in academic research due to the pandemic. Please see our results of operations discussion below for additional information. We expect demand for our products and services across all of our reporting segments, and in particular our Global Logistics Services segment to be adversely impacted for as long as global economic activity and trade volumes remain weak. A prolonged slowdown in trade volumes due to the pandemic could also significantly increase the financial challenges facing our customers. We are closely monitoring our customers’ payment performance and expect our customer credit risk will remain high as long as economic and trade disruptions persist.
In our Global Logistics Services segment, customer demand for our services in many parts of our business has been materially and negatively impacted by the mandated closure of our customers’ operations or points of sale, while customer demand for our services in other parts of our business has increased significantly as consumers stockpile goods or switch to e-commerce platforms to make purchases. We are unable to accurately predict the impact that COVID-19 will have on our operations going forward due to uncertainties regarding the severity and duration of the outbreak and additional actions that may be taken by governmental authorities. That said, we currently expect that our results of operations and financial condition will be even more significantly adversely impacted in the third quarter and fourth quarters of 2020 and subsequent periods than in the quarter ended March 31, 2020, as levels of activity in the Company’s business have historically been positively correlated to broad measures of economic activity, such as gross domestic product, and to measures of industrial economic activity, which have been negatively impacted by the pandemic.
The magnitude of the COVID-19 pandemic, including the extent of any impact on our business, financial position, results of operations or liquidity, which could be material, cannot be reasonably determined at this time due to the rapid development and fluidity of the situation. The effects of the pandemic on our business will depend on its duration and severity, whether business disruptions will continue, the pace of recovery once the pandemic subsides and the overall long-term impact on the global economy.
OVERVIEW
Janel is a holding company with subsidiaries in three business segments: Global Logistics Services, Manufacturing and Life Sciences. The company strives to create shareholder value primarily through three strategic priorities: supporting its businesses’ efforts to make investments and to build long-term profits; allocating Janel’s capital at high risk-adjusted rates of return; and attracting and retaining exceptional talent.
A management group at the holding company level (the “corporate group”) focuses on significant capital allocation decisions, corporate governance and supporting Janel’s subsidiaries where appropriate. Janel expects to grow through its subsidiaries’ organic growth and by completing acquisitions. We plan to either acquire businesses within our existing segments or expand our portfolio into new strategic segments. Our acquisition strategy focuses on reasonably-priced companies with strong and capable management teams, attractive existing business economics and stable and predictable earnings power.
Global Logistics Services
The Company’s Global Logistics Services segment is comprised of several wholly-owned subsidiaries (collectively “Janel Group”). Janel Group is a non-asset based, full-service provider of cargo transportation logistics management services, including freight forwarding via air-, ocean- and land-based carriers, customs brokerage services, warehousing and distribution services, and other value-added logistics services.
On November 20, 2018, we completed a business combination whereby we acquired the membership interest of Honor Worldwide Logistics, LLC (“Honor”), a global logistics services provider with two U.S. locations.
On October 17, 2018, we completed a business combination whereby we acquired substantially all of the assets and certain liabilities of a global logistics services provider with one U.S. location.
Manufacturing
The Company’s Manufacturing segment is comprised of Indco, Inc. (“Indco”). Indco is a majority-owned subsidiary of the Company that manufactures and distributes mixing equipment and apparatus for specific applications within various industries. Indco’s customer base is comprised of small- to mid-sized businesses as well as other larger customers for which Indco fulfills repetitive production orders.
Life Sciences
The Company’s Life Sciences segment is comprised of Aves Labs, Inc. (“Aves”), Antibodies Incorporated (“Antibodies”), IgG, LLC (“IgG”) and PhosphoSolutions, LLC, which are wholly-owned subsidiaries of the Company.
The Company’s Life Sciences segment manufactures and distributes high-quality monoclonal and polyclonal antibodies, diagnostic reagents and other immunoreagents for biomedical research and provides antibody manufacturing for academic and industry research scientists. Our Life Sciences business also produces products for other life science companies on an original equipment manufacturer (“OEM”) basis.
Through Aves, the Company acquired the membership interests of a small life sciences company on July 1, 2019 and the equity interests of PhosphoSolutions, LLC. (“Phospho”) on September 6, 2019. Both acquisitions were completed primarily to expand our product offerings in Life Sciences.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Critical accounting estimates are those that we believe are both significant and require us to make difficult, subjective or complex judgments, often because we need to estimate the effect of inherently uncertain matters. These estimates are based on historical experience and various other factors that we believe to be appropriate under the circumstance. Actual amounts and results could differ from these estimates made by management. Certain accounting policies that require significant management estimates and are deemed critical to our results of operations or financial position are discussed in the Critical Accounting Policies and Estimates section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Item 7 of our Annual Report on Form 10-K for the fiscal year ended September 30, 2019.
The Company’s consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires management to make estimates and assumptions about future events that affect the amounts reported in the financial statements and accompanying notes. Since future events and their effects cannot be determined with absolute certainty, the determination of estimates requires the exercise of judgment. Actual results could differ from those estimates, and such differences may be material to the financial statements. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to revenue recognition, the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources, primarily allowance for doubtful accounts, accruals for transportation and other direct costs, accruals for cargo insurance, and deferred income taxes. Management bases its estimates on historical experience and on various assumptions which are believed to be reasonable under the circumstances. We reevaluate these significant factors as facts and circumstances change. Note 1 of the notes to consolidated financial statements included herein includes a summary of the significant accounting policies and methods used in the preparation of our consolidated financial statements. The following is a brief discussion of certain accounting policies and estimates.
Management believes that the nature of the Company’s business is such that there are a few complex challenges in accounting for operations. Revenue recognition is considered the critical accounting policy due to the complexity of arranging and managing global logistics and supply-chain management transactions.
Income taxes
The Company uses the asset and liability method of accounting for income taxes in accordance with Accounting Standards Codification Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date.
Estimates
While judgments and estimates are a necessary component of any system of accounting, the Company’s use of estimates is limited primarily to the following areas that in the aggregate are not a major component of the Company’s consolidated statements of operations:

•
accounts receivable valuation;

•
the useful lives of long-term assets;

•
the accrual of costs related to ancillary services the Company provides;

•
accrual of tax expense on an interim basis; and

•
inventory valuation.
Management believes that the methods utilized in these areas are consistent in application. Management further believes that there are limited, if any, alternative accounting principles or methods which could be applied to the Company’s transactions. While the use of estimates means that actual future results may be different from those contemplated by the estimates, the Company believes that alternative principles and methods used for making such estimates would not produce materially different results than those reported.
Critical Accounting Policies and Estimates Applicable to the Global Logistics Services Segment
Revenue Recognition
Revenues are derived from customs brokerage services and from freight forwarding services.
Customs brokerage services include activities required for the clearance of shipments through government customs regimes, such as preparing required documentation, calculating and providing for payment of duties and other charges on behalf of customers, arranging required inspections and arranging final delivery.
Freight forwarding may require multiple services, including long-distance shipment via air, ocean or ground assets, destination handling (“break bulk”), warehousing, distribution and other logistics management activities. As an asset-light business, Janel Group owns none of the assets by which it fulfills its customers’ logistics needs. Rather, it purchases the services its customers need from asset owners, such as airlines and steamship lines, and resells them. By consolidating shipments from multiple customers, Janel Group can negotiate terms of service with asset owners that are more favorable than those the customers could negotiate themselves.
Revenue is recognized upon transfer of control of promised services to customers. With respect to its Global Logistics Services segment, t he Company has determined that in general each shipment transaction or service order constitutes a separate contract with the customer. When the Company provides multiple services to a customer, different contracts may be present for different services.
The Company typically satisfies its performance obligations as services are rendered at a point in time. A typical shipment would include services rendered at origin, such as pick-up and delivery to port, freight services from origin to destination port and destination services, such as customs clearance and final delivery. The Company measures the performance of its obligations as services are completed at a point in time during the life of a shipment, including services at origin, freight and destination. The Company fulfills nearly all of its performance obligations within a one-to two-month period.
The Company evaluates whether amounts billed to customers should be reported as gross or net revenue. Generally, revenue is recorded on a gross basis when the Company is primarily responsible for fulfilling the promise to provide the services, when it has discretion in setting the prices for the services to the customers, and the Company has the ability to direct the use of the services provided by the third party. Revenue is recognized on a net basis when we do not have latitude in carrier selection or establish rates with the carrier.
In the Global Logistics Services segment, the Company disaggregates its revenues by its four primary service categories: ocean import and export, freight forwarding, customs brokerage and air import and export.

Critical Accounting Policies and Estimates Applicable to the Manufacturing and Life Sciences Segments
Revenue Recognition-Manufacturing

Revenues from Indco are derived from the engineering, manufacture and delivery of specialty mixing equipment and accessories. Indco receives customer product orders via telephone, email, internet or fax. The pricing of each standard product sold is listed in Indco’s print and web-based catalog. Customer specific products are priced by quote. A sales order acknowledgement is sent to every customer for every order to confirm pricing and the specifications of the products ordered. The revenue is recognized at a point in time when the product is shipped to the customer.

Revenue Recognition-Life Sciences

Revenues from the Life Sciences segment are derived from the sale of high-quality monoclonal and polyclonal antibodies, diagnostic reagents and diagnostic kits and other immunoreagents for biomedical research and antibody manufacturing. Revenues are recognized when products are shipped and risk of loss is transferred to the carrier(s) used.
NON-GAAP FINANCIAL MEASURES
While we prepare our financial statements in accordance with U.S. GAAP, we also utilize and present certain financial measures, in particular adjusted operating income, which is not based on or included in U.S. GAAP (we refer to these as “non-GAAP financial measures”).
Net Revenue
Net revenue is a non-GAAP measure calculated as total revenue less forwarding expenses attributable to the Company’s Global Logistics Services segment. Our total revenue represents the total dollar value of services and goods we sell to our customers. Forwarding expenses attributable to the Company’s Global Logistics Services segment refer to purchased transportation and related services including contracted air, ocean, rail, motor carrier and other costs. Total revenue can be influenced greatly by changes in transportation rates or other items, such as fuel prices, which we do not control. Management believes that providing net revenue is useful to investors as net revenue is the primary indicator of our ability to source, add value and sell services and products that are provided by third parties, and we consider net revenue to be our primary performance measurement. The difference between the rate billed to our customers (the sell rate) and the rate we pay to the carrier (the buy rate) is termed “net revenue”, “yield” or “margin.” As presented, net revenue matches gross margin.
Adjusted Operating Income
As a result of our acquisition strategy, our net income includes material non-cash charges relating to the amortization of customer-related intangible assets in the ordinary course of business as well as other intangible assets acquired in our acquisitions. Although these charges may increase as we complete more acquisitions, we believe we will be growing the value of our intangible assets such as customer relationships. Because these charges are not indicative of our operations, we believe that adjusted operating income is a useful financial measure for investors because it eliminates the effect of these non-cash costs and provides an important metric for our business that is more representative of the actual results of our operations.
Adjusted operating income (which excludes the non-cash impact of amortization of intangible assets, stock-based compensation and amortization of acquired inventory valuation) is used by management as a supplemental performance measure to assess our business’s ability to generate cash and economic returns.
Adjusted operating income is a non-GAAP measure of income and does not include the effects of preferred stock dividends, interest and taxes.
We believe that net revenue and adjusted operating income provide useful information in understanding and evaluating our operating results in the same manner as management. However, net revenue and adjusted operating income are not financial measures calculated in accordance with U.S. GAAP and should not be considered as a substitute for total revenue, operating income or any other operating performance measures calculated in accordance with U.S. GAAP. Using these non-GAAP financial measures to analyze our business has material limitations because the calculations are based on the subjective determination of management regarding the nature and classification of events and circumstances that users of the financial statements may find significant.
In addition, although other companies in our industry may report measures titled net revenue, adjusted operating income or similar measures, such non-GAAP financial measures may be calculated differently from how we calculate our non-GAAP financial measures, which reduces their overall usefulness as comparative measures. Because of these limitations, you should consider net revenue and adjusted operating income alongside other financial performance measures, including total revenue, operating income and our other financial results presented in accordance with U.S. GAAP.
The following table sets forth a reconciliation of operating income to adjusted operating income:
Three Months Ended
March 31,
Six Months Ended
March 31,
2020
2019
2020
2019
(in thousands)
(in thousands)
Operating (loss) income
$
(831
)
$
442
$
(872
)
$
1,332
Amortization of intangible assets (1)
243
236
486
444
Stock-based compensation (2)
75
107
149
236
Amortization of acquired inventory valuation (3)
227
67
447
129
Adjusted operating income
$
(286
)
$
852
$
210
$
2,141

(1)
Amortization of intangible assets represents non-cash amortization expense or impairment expense, if any, attributable to acquisition-related intangible assets, including any portion that is allocated to noncontrolling interests. Management believes that making this adjustment aids in comparing the Company’s operating results with other companies in our industry that have not engaged in acquisitions.
(2)
The Company eliminates the impact of stock-based compensation because it does not consider such non-cash expenses to be indicative of the Company’s core operating performance. The exclusion of stock-based compensation expenses also facilitates comparisons of the Company’s underlying operating performance on a period-to-period basis.
(3)
The Company has excluded the impact of amortization of acquired inventory valuation in connection with acquisitions as such adjustments represent non-cash items, are not consistent in amount and frequency and are significantly impacted by the timing and size of the Company’s acquisitions.
Results of Operations – Segment Financial Results – Three and Six Months Ended March 31, 2020 and 2019
The following table sets forth our segment financial results:
Three Months Ended
March 31,
Six Months Ended
March 31,
2020
2019
2020
2019
(in thousands)
Revenue:
Global Logistics Services
$
15,328
$
16,865
$
31,407
$
35,670
Manufacturing
2,056
2,452
3,926
4,533
Life Sciences
1,737
1,652
3,609
3,093
Total Revenues
19,121
20,969
38,942
43,296
Gross Profit:
Global Logistics Services
3,713
3,908
7,705
8,295
Manufacturing
1,148
1,375
2,173
2,523
Life Sciences
1,135
1,087
2,405
2,039
Total Gross Profit
5,996
6,370
12,283
12,857
Income (loss) from Operations:
Global Logistics Services
(239
)
440
115
1,467
Manufacturing
447
616
790
1,056
Life Sciences
64
363
354
608
Total Income from Operations by Segment
272
1,419
1,259
3,131
Corporate administrative expense
(860
)
(741
)
(1,645
)
(1,355
)
Amortization expense
(243
)
(236
)
(486
)
(444
)
Interest expense, net
(141
)
(198
)
(304
)
(360
)
Net (loss) income before taxes
(972
)
244
(1,176
)
972
Income tax benefit (expense)
35
(69
)
119
(253
)
Net (loss) income
$
(937
)
$
175
$
(1,057
)
$
719
Preferred stock dividends
(175
)
(148
)
(326
)
(270
)
Net (Loss) Income available to Common Stockholders
$
(1,112
)
$
27
$
(1,383
)
$
449

Results of Operations – Janel Corporation
The following table sets forth our corporate group expenses:
Three Months Ended
March 31,
Six Months Ended
March 31,
2020
2019
2020
2019
(in thousands)
Corporate expenses
$
785
$
582
$
1,470
$
1,045
Amortization of intangible assets
243
236
486
444
Stock-based compensation
37
142
111
236
Merger and acquisition expenses
38
17
64
74
Total corporate expenses
$
1,103
$
977
$
2,131
$
1,799

Expenses
Corporate expenses, which include amortization of intangible assets, stock-based compensation and merger and acquisition expenses, increased by $126 to $1,103, or 12.9% in the three months ended March 31, 2020 as compared to $977 for the three months ended March 31, 2019. Expenses increased to $2,131 in the six months ended March 31, 2020 as compared to $1,799 in the six months ended March 31, 2019, a $332 or 18.5% increase. The increases in both periods were due primarily to higher accounting-related professional expenses and higher merger and acquisition related expenses partially offset by lower stock-based compensation expense for the quarter.
Amortization of Intangible Assets
For the three months ended March 31, 2020 and 2019, corporate amortization expenses were $243 and $236, respectively, an increase of $7, or 3.0%. For the six months ended March 31, 2020 and 2019, corporate amortization expenses were $486 and $444, respectively, an increase of $42, or 9.5%. The increases in both periods were primarily related to acquisitions.
Interest Expense
For the three months ended March 31, 2020, interest expense for the consolidated company decreased $57, or 28.9%, to $141 from $198 for the three months ended March 31, 2019. For the six months ended March 31, 2020 and 2019, interest expense was $304 and $360, respectively, a decrease of $56, or 15.5%. The decrease in both periods was primarily due to lower prevailing interest rates and lower rates on the amended revolving line of credit facility, partially offset by average higher debt levels on the senior secured term loan facility.
Income Taxes
On a consolidated basis, the Company recorded an income tax benefit of $35 for the three months ended March 31, 2020, as compared to an income tax expense of $69 for the three months ended March 31, 2019. For the six months ended March 31, 2020, the Company recorded an income tax benefit of $119 versus an expense of $253 in the prior year period. The income tax benefit in both periods was primarily due to the increase in pretax loss. In 2016, a deferred tax asset was established to reflect a net operating loss carryforward, which the Company has begun using, and is expected to continue to use, through ongoing profitability.
Preferred Stock Dividends
Preferred stock dividends include any dividends accrued but not paid on the Company’s Series C Cumulative Preferred Stock (the “Series C Stock”). For the three months ended March 31, 2020 and 2019, preferred stock dividends were $175 and $148, respectively. For the six months ended March 31, 2020 and 2019, the preferred stock dividends we $326 versus $270, respectively. The increase of $27 for the three-month period and $56 for the six-month period were the result of an increase in the dividend rate as of January 1, 2020 to 7% and a higher outstanding amount of accrued and unpaid dividends. See note 9 to the consolidated financial statements for additional information.
Net (Loss) Income
Net loss was ($937) or ($1.08) per diluted share, for the three months ended March 31, 2020 compared to net income of $175, or $0.18 per diluted share, for the three months ended March 31, 2019. For the six months ended March 31, 2020, net (loss) income totaled ($1,057) or ($1.22) per share compared to $719 or $0.77 per share for the six months ended March 31, 2019. The loss was primarily due to lower revenues and gross profit and higher selling, general and administrative expenses across our businesses in both periods.
(Loss) Income Available to Common Stockholders
Loss available to holders of common shares was ($1,112), or ($1.29) per diluted share, for the three months ended March 31, 2020 compared to income of $27, or $0.03 per diluted share, for the three months ended March 31, 2019. In the six months ended March 31, 2020 loss available to holders of common shares totaled ($1,383) or ($1.60) per share compared to $449 or $0.48 per share for the six months ended March 31, 2019. The decrease primarily was due to lower revenues and gross profit and higher selling, general and administrative expenses across our businesses in both periods and an increase in the dividend rate with respect to the Series C Stock as of January 1, 2020 to 7%.
Results of Operations - Global Logistics Services
Our Global Logistics Services business helps its clients move and manage freight efficiently to reduce inventories and to increase supply chain speed and reliability. Key services include customs entry filing, arrangement of freight forwarding by air, ocean and ground, warehousing, cargo insurance procurement, logistics planning, product repackaging and online shipment tracking.
Global Logistics Services – Selected Financial Information:
Three Months Ended
March 31,
Six Months Ended
March 31,
2020
2019
2020
2019
(in thousands)
Revenue
$
15,328
$
16,865
$
31,407
$
35,670
Forwarding expenses
11,615
12,957
23,702
27,375
Net revenue
3,713
3,908
7,705
8,295
Gross profit margin
24.2
%
23.2
%
24.5
%
23.3
%
Selling, general & administrative
3,952
3,468
7,590
6,828
(Loss) income from operations
$
(239
)
$
440
$
115
$
1,467

Revenue
Total revenue decreased 9.1% to $15,328 for the three months ended March 31, 2020, compared to $16,865 in the three months ended March 31, 2019. The decrease in revenue was driven by the global trade slowdown, in particular the steep reductions in global import and export trade volumes, due to the COVID-19 pandemic.
Total revenue for the six months ended March 31, 2020 and 2019 was $31,407 and $35,670 respectively, a decrease of $4,263 or 11.9%. The decrease in revenue was largely due to the impact of the global trade slowdown due to the COVID-19 pandemic and customers in the prior year period moving freight ahead of certain governmental trade policies. Acquired revenue from two acquisitions completed during fiscal 2019 slightly offset some of the revenue decline in the six-month period.
Net Revenue
Net revenue for the three months ended March 31, 2020 and 2019 was $3,713 and $3,908 respectively, a decrease of $195, or 5.0%. The decrease reflected an organic decline for the quarter in our base business due to volume pressures from the COVID-19 pandemic partially offset by improved freight purchase rates. Net revenue as a percentage of gross revenue increased to 24.2% versus 23.2% for the prior year period due to lower freight rates.
Net revenue for the six months ended March 31, 2020 and 2019 was $7,705 and $8,295 respectively, a decrease of $590, or 7.1%, as a result of organic declines due to the COVID-19 pandemic partially offset by contributions from two acquisitions and improved freight purchase rates in the current year period, whereas we benefited in the prior year period from customers moving freight in advance of certain governmental trade policies. Net revenue as a percentage of gross revenue increased in the six-month period to 24.5% versus 23.3% in the prior year period due to lower freight rates.
Selling, General and Administrative Expenses
Selling, general and administrative expenses for the three months ended March 31, 2020 were $3,952, as compared to $3,468 for the three months ended March 31, 2019. This increase of $484, or 14.0%, was largely attributable to the reserve for the settlement of threatened litigation and additional expenses from maintaining current staff levels. As a percentage of revenue, selling, general and administrative expenses were 25.8% and 20.6% of revenue for the three months ended March 31, 2020 and 2019, respectively.
Selling, general and administrative expenses for the six months ended March 31, 2020 and 2019 were $7,590 and $6,828 respectively. The increase of $762, or 11.16% reflected the reserve for the settlement of threatened litigation and higher expenses from prior year acquisitions. As a percentage of revenue, selling, general and administrative expenses were 24.2% and 19.1% of revenue for the six months ended March 31, 2019 and 2018, respectively.
(Loss) Income from Operations
For the three months ended March 31, 2020, loss from operations before income taxes was $(239) as compared to income from operations of $440 for the three months ended March 31, 2019, a decrease of $679 or 154.3%. Operating income in the three-month period declined due to the impact of the global trade slowdown associated with the COVID-19 pandemic and the reserve for the settlement of threatened litigation.
For the six months ended March 31, 2020 and 2019, income from operations before income taxes was $115 and $1,467 respectively, a decrease of $1,352 or 92.2%. Income from operations declined as a result of the impact of the COVID-19 pandemic, a shift in volume experienced during the first quarter of fiscal 2019 that did not recur and the reserve for the settlement of threatened litigation, partially offset by contributions from acquisitions experienced during the first quarter. Our operating margin as a percentage of net revenue for the three months ended March 31, 2020 was 6.4%, versus 11.3% in the prior year period.
Results of Operations - Manufacturing
The Company’s Manufacturing segment includes its majority-owned Indco subsidiary, which manufactures and distributes industrial mixing equipment.
Manufacturing – Selected Financial Information:
Three Months Ended
March 31,
Six Months Ended
March 31,
2020
2019
2020
2019
(in thousands)
Revenue
$
2,056
$
2,452
$
3,926
$
4,533
Cost of sales
908
1,077
1,753
2,010
Gross profit
1,148
1,375
2,173
2,523
Gross profit margin
$
55.8
%
$
56.1
%
55.3
%
55.7
%
Selling, general & administrative
701
759
1,383
1,467
Income from Operations
$
447
$
616
$
790
$
1,056

Revenue
Total revenue decreased 16.1% to $2,056 in the three months ended March 31, 2020, compared to $2,452 for the three months ended March 31, 2019. Total revenue decreased 13.4% to $3,926 in the six months ended March 31, 2019, compared to $4,533 in the six months ended March 31, 2018. The revenue decline in both periods reflected a decline in volume across the business relative to the prior year periods, due to the slowdown late in the quarter related to the COVID-19 pandemic.
Gross Profit
Gross profit decreased 16.5% to $1,148 in the three months ended March 31, 2020, compared to $1,375 for the three months ended March 31, 2019. Gross profit margin for the three-month periods ended March 31, 2020 and 2019 was 55.8% and 56.1%, respectively. Gross profit margin for the six months ended March 31, 2020 decreased to 55.3%, compared to 55.7% for the six months ended March 31, 2019. In both the three- and six-month periods, gross profit margin was relatively flat as the mix of business remained consistent.
Selling, General and Administrative Expenses
Selling, general and administrative expenses decreased 7.6% to $701 in the three months ended March 31, 2020, compared to $759 in the three months ended March 31, 2019. Selling, general and administrative expenses decreased 5.7% to $1,383 in the six months ended March 31, 2020, compared to $1,467 in the six months ended March 31, 2020. The decrease in both periods was related to the decline in revenue, partially offset by management’s decision to maintain operational capabilities.
Income from Operations
Income from operations was $447 for the three months ended March 31, 2020 compared to $616 for the three months ended March 31, 2019, representing a 27.4% decrease from the prior year period. Income from operations of $790 for the six months ended March 31, 2020 decreased 25.2% compared to $1,056 for the six months ended March 31, 2019. Operating profit decreased in both periods due to lower revenue growth without corresponding expense reductions.
Results of Operations – Life Sciences
The Company’s Life Sciences segment manufactures and distributes high-quality monoclonal and polyclonal antibodies, diagnostic reagents and other immunoreagents for biomedical research and provides antibody manufacturing for academic and industry research scientists. Our Life Sciences business also produces products for other life science companies on an OEM basis.
Life Sciences – Selected Financial Information:
Three Months Ended
March 31,
Six Months Ended
March 31,
2020
2019
2020
2019
(in thousands)
Revenue
$
1,737
$
1,652
$
3,609
$
3,093
Cost of sales
602
565
1,204
1,054
Gross profit
1,135
1,087
2,405
2,039
Gross profit margin
65.3
%
65.8
%
66.6
%
65.9
%
Selling, general & administrative
1,071
724
2,051
1,431
Income from Operations
$
64
$
363
$
354
$
608

Revenue
Total revenue was $1,737 and $1,652 for the three months ended March 31, 2020 and 2019, respectively, an increase of $85 or 5.1%. Total revenue was $3,609 and $3,093 for the six months ended March 31, 2020 and 2019, respectively. Acquisitions accounted all of the increase in both periods, as organic growth declined at a double-digit rate for the quarter and at a mid-single digit rate in the six-month period, each as compared to the prior year period, due to the slowdown in academic research late in the quarter related to the COVID-19 pandemic.
Gross Profit and Gross Profit Margin
Gross profit was $1,135 and $1,087 for the three months ended March 31, 2020 and 2019 , respectively, an increase of $48 or 4.4%. Amortization of acquired inventory in the quarter totaled $227 versus $67 in the prior year period due to our two prior year acquisitions. I n the three months ended March 31, 2020 and 2019, the Life Sciences segment had gross profit margins of 65.3% and 65.8%, respectively. Gross profit margin decreased in the quarter compared to prior year period due to acquisitions and favorable product mix.
Gross profit was $2,405 and $2,039 for the six months ended March 31, 2020 and 2019, respectively. In the six months ended March 31, 2020 the amortization of acquired inventory totaled $447 versus $129 in the prior year. In the six months ended March 31, 2020, the Life Sciences segment had a gross profit margin of 66.6% compared to 65.9% for the prior year period.

Selling, General and Administrative Expenses
Selling, general and administrative expenses were $1,071 and $724 for the three months ended March 31, 2020 and 2019, respectively, an increase of $347 or 47.9%, largely due to acquired businesses. Selling, general and administrative expenses were $2,051 and $1,431 for the six months ended March 31, 2020 and 2019, respectively. The increase was largely due to acquired businesses.
Income from Operations
Income from operations for the three months ended March 31, 2020 and 2019 was $64 compared to $363, in the prior year. The decline in operating income reflected higher amortization of acquired inventory due to acquisitions and a slowdown in academic research late in the quarter related to the COVID-19 pandemic. Income from operations for the six months ended March 31, 2020 and 2019 was $354 and $608, respectively. The decline reflected higher amortization of acquired inventory due to acquisitions. As a percentage of revenue income from operations in the six months ended March 31, 2020 declined to 9.8% versus 19.7% due to higher amortization of acquired inventory. Absent these non-cash expenses, adjusted operating income increased to $801 versus $736 in the prior year period due to acquisitions, offset by lower organic revenue.
LIQUIDITY AND CAPITAL RESOURCES
General
Our ability to satisfy liquidity requirements, including satisfying debt obligations and fund working capital, day-to-day operating expenses and capital expenditures, depends upon future performance, which is subject to general economic conditions, competition and other factors, some of which are beyond Janel’s control. Our Global Logistics Services segment depends on commercial credit facilities to fund day-to-day operations as there is a difference between the timing of collection cycles and the timing of payments to vendors. Generally, Janel does not make significant capital expenditures.
As a customs broker, our Global Logistics Services segment makes significant cash advances for a select group of our credit-worthy customers. These cash advances are for customer obligations such as the payment of duties and taxes to customs authorities primarily in the U.S. Increases in duty rates could result in increases in the amounts we advance on behalf of our customers. Cash advances are a “pass through” and are not recorded as a component of revenue and expense. The billings of such advances to customers are accounted for as a direct increase in accounts receivable from the customer and a corresponding increase in accounts payable to governmental customs authorities. These “pass through” billings can influence our traditional credit collection metrics. For customers that meet certain criteria, we have agreed to extend payment terms beyond our customary terms. Management believes that it has established effective credit control procedures and has historically experienced relatively insignificant collection problems.
The COVID-19 pandemic has negatively impacted our liquidity and cash flows. As discussed in greater detail in note 17 to the consolidated financial statements, on April 19, 2020, we entered into a loan agreement with Santander and executed a U.S. Small Business Administration Note pursuant to which we borrowed $2,726 from Santander pursuant to the Paycheck Protection Program under The Coronavirus Aid, Relief and Economic Security Act, Section 7(a)(36) of the Small Business Act in order to be able to continue to cover our payroll costs, group health care benefits, mortgage payments, rent and utilities. The duration and magnitude of the pandemic is not reasonably estimable at this point, and if the pandemic persists, our liquidity and capital resources could be further negatively impacted.
As of March 31, 2020, the Company’s cash and working capital deficiency (current assets minus current liabilities) were $1,928 and $8,302, respectively, as compared to $2,163 and $6,190 as of September 30, 2019. The increase in working capital deficiency is considered nominal, representing relatively stable collections from customers and payments of vendors.
Janel’s cash flow performance for the three and six-months ended March 31, 2020 is not necessarily indicative of future cash flow performance.
Cash flows from operating activities
Net cash provided by operating activities for the six months ended March 31, 2020 and 2019 was $1,209 and $1,272, respectively. The decrease in cash provided by operations for the six months ended March 31, 2020 was driven principally by the higher net loss, partially offset by timing of cash collections for accounts receivables and cash payments on accounts payables for the six-month period ended March 31, 2020.
Cash flows from investing activities
Net cash used in investing activities totaled $247 for the six months ended March 31, 2020, versus $2,188 for the prior year period. During the six months ended March 31, 2020, the Company used $116 for final purchase price adjustments related to an acquisition in the prior year compared to $1,935 for the six months ended March 31, 2019. The Company also used $131 for the acquisition of property and equipment for the six months ended March 31, 2020 compared to $253 for the six months ended March 31, 2019.
Cash flows from financing activities
Net cash used in financing activities was ($1,197) for the six months ended March 31, 2020, versus $1,712 provided by financing activities for the six months ended March 31, 2019. Net cash used in financing activities for the six months ended March 31, 2020 was primarily a result of reduced outstanding balances on our line of credit. Net cash provided by financing activities for the six months ended March 31, 2019 primarily funded our acquisition efforts.
Off-Balance Sheet Arrangements
As of March 31, 2020, we had no off-balance sheet arrangements or obligations.
ITEM 4.
CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
The Company maintains disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the specified time periods, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives.
Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of March 31, 2020, the end of the period covered by this Quarterly Report on Form 10-Q. Based on this evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that, because material weaknesses in the Company’s internal control over financial reporting existed at September 30, 2018 and had not been remediated by the end of the period covered by this Quarterly Report on Form 10-Q, the Company’s disclosure controls and procedures were not effective as of the end of the period covered by this Quarterly Report on Form 10-Q.  These material weaknesses in the Company’s internal control over financial reporting and the Company’s remediation efforts are described below.
Material Weaknesses in Internal Control Over Financial Reporting
The Company’s management, including our Chief Executive Officer and Chief Financial Officer, have identified material weaknesses in the Company’s internal control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis.
In connection with the preparation of the Company’s Annual Report on Form 10-K, management identified the following material weaknesses as of September 30, 2019 related to our Life Sciences segment:

•
The Company had inadequate controls over the following:
(1) recording of sales orders and timeliness of revenue recognition in accordance with ASC Topic 606, Revenue from Contracts with Customers – Principal Agent Consideration (“ASC Topic 606”),
(2) recording of journal entries and approvals,
(3) payroll recording and processing of payroll changes,
(4) vendor setup and creation,
(5) documentation of inventory cycle count results, and
(6) recording of inventory and updating of standard costing worksheets used in the valuation of inventory.

•
A number of deficiencies were identified related to the design, implementation and effectiveness of certain information technology general controls, including segregation of duties, user access, change management, data back-ups and review of SOC 1 and 2 reports from critical vendors, some of which could have a direct impact on the Company’s financial reporting.
In addition, as of September 30, 2019, management identified the following additional deficiency related to the Company’s Global Logistics Services segment:

•
Management did not have an effective process or control in place to perform an assessment of gross versus net revenue recognition criteria in accordance with ASC Topic 606.
Based on this assessment and the material weaknesses described above, management concluded that the Company’s internal control over financial reporting was not effective as of September 30, 2019 and had not been remediated by the end of the period covered by this Quarterly Report on Form 10-Q.
Our management performed analyses, substantive procedures and other post-closing activities with the assistance of consultants and other professional advisors in order to ensure the validity, completeness and accuracy of our income tax provision and accounting for complex and/or non-routine transactions and the related disclosures. Accordingly, our management believes that the financial statements included in this Form 10-Q as of March 31, 2020 are fairly presented, in all material respects, and in conformity with U.S. GAAP.
Remediation Plan
We have engaged an external consultant to assist in the development and execution of a plan to remediate the material weaknesses related to our Life Sciences segment noted above. This process commenced during the second quarter of fiscal 2020 and is ongoing.
We have developed and are executing on our plan to remediate our material weaknesses in connection with the information technology controls by expanding our in-house expertise on information technology general controls, as well as continuing to consult with external third parties. This process commenced during the fourth quarter of fiscal 2018 and is ongoing.
We have also implemented a new system triggered revenue recognition process for the Global Logistics Services segment based on target dates (e.g., delivery date, file transfer date, etc.) for specific file types. This process has been implemented as the second quarter of fiscal year 2020.
Our management believes that the foregoing efforts will effectively remediate the material weaknesses. That said, the new and enhanced controls have not operated for a sufficient amount of time to conclude that the material weaknesses have been remediated.  As we continue to evaluate and work to improve our internal control over financial reporting, our management may decide to take additional measures to address the material weaknesses or modify the remediation plan described above.
Internal control over financial reporting, no matter how well designed, has inherent limitations. Therefore, even those controls determined to be effective may not prevent or detect misstatements and can provide only reasonable assurance with respect to financial statement preparation and presentation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Our executive management team, together with our board of directors, is committed to achieving and maintaining a strong control environment, high ethical standards, and financial reporting integrity.
Changes in Internal Control over Financial Reporting
As disclosed above under “Remediation Plan,” there were changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. In addition, as discussed above, during the quarter ended March 31, 2020, the Company implemented changes to its accounting policies, practices and internal controls over financial reporting in connection with its adoption of ASC Topic 606.
PART II - OTHER INFORMATION
ITEM 1.
LEGAL PROCEEDINGS
Janel is occasionally subject to claims and lawsuits which typically arise in the normal course of business. While the outcome of these claims cannot be predicted with certainty, management does not believe that the outcome of any of these legal matters will have a material adverse effect on the Company’s business, results of operations, financial condition or cash flows.
In December 2017, Janel Group received a Notice of Copyright Infringement letter from counsel for Warren Communications News, Inc. (“Warren”), the publisher of the International Trade Today (“ITT”) newsletter. On May 11, 2020, the parties reached a settlement agreement and release to resolve any and all concerns between the parties, voluntarily and without admission of copyright infringement.
As of March 31, 2020, the Company had a liability for settlement costs related to the Warren Matter, which is included in accrued expenses and other current liabilities.

ITEM 1A.
RISK FACTORS
For a discussion of the Company’s potential risks or uncertainties, please see “Part I—Item 1A—Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended September 30, 2019 filed with the SEC. Other than as described below, there have been no material changes to the risk factors disclosed in Part I—Item 1A of the Company’s 2019 Annual Report.
The coronavirus pandemic has significantly impacted worldwide economic conditions and has had, and is likely to continue to have, an adverse effect on our business operations, results of operations, cash flows and financial position.

In December 2019, a novel coronavirus (COVID-19) outbreak was reported in China, and, in March 2020, the World Health Organization declared such outbreak a pandemic. Since that time, the coronavirus has spread throughout the United States and globally, including in the regions and communities in which we operate. We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business and geographies, including how it has and will continue to impact our customers, suppliers, employees and other business partners. The COVID-19 pandemic has created significant volatility, uncertainty and economic disruption, which will adversely affect our business operations and has, and is likely to continue to, adversely affect our results of operations, cash flows and financial position.  COVID-19 has spread to regions that are important to our business in terms of sales, manufacturing, and our supply chain, and many of the affected regions, including the region in which our headquarters are located, are currently under government-imposed ‘stay at home’ orders which may restrict our ability to continue normal business operations.  Further, our management is focused on mitigating the effects of COVID-19 on our business operations while protecting the health of our employees, which has required and will continue to require, a significant investment of time and resources across our enterprise.
In our Global Logistics Services segment, customer demand for our services in many parts of our business has been materially and negatively impacted by the mandated closure of our customers’ operations or points of sale, while customer demand for our services in other parts of our business has increased significantly as consumers stockpile goods or switch to e-commerce platforms to make purchases. We are unable to accurately predict the impact that COVID-19 will have on our operations going forward due to uncertainties regarding the severity and duration of the outbreak and additional actions that may be taken by governmental authorities. That said, we currently expect that our results of operations and financial condition will be even more significantly adversely impacted in the third quarter and fourth quarters of 2020 and subsequent periods than in the quarter ended March 31, 2020, as levels of activity in the Company’s business have historically been positively correlated to broad measures of economic activity, such as gross domestic product, and to measures of industrial economic activity, which have been negatively impacted by the pandemic.
Additionally, we have seen a material impact in our Life Sciences business as a result of a slowdown in academic research due to the pandemic. We may also see adverse impact on our ability (a) to manufacture, test and ship our products in our Life Sciences and Manufacturing businesses, (b) to get required materials and components to make our products in our Manufacturing and Life Sciences segments, and (c) to staff labor and management for manufacturing, supply chain, research and development and administrative operations.  Further, we may experience adverse impact with our global supply chain partners and transportation service providers.  Any extended pandemic outbreak, such as is occurring with COVID-19, could cause our key third-party suppliers or the Company itself to temporarily close one or more offices or manufacturing facilities. In addition, there has been a significant decline in trade shows worldwide and also a significant decline in our ability to travel to visit current and potential customers, which will adversely affect our ability to create leads and generate business. Also, in some cases, our customers have suspended operations or limited our ability to come on-site. Furthermore, we may not be able to maintain for an extended period of time our efforts to have employees work at home and operate reduced workforces at facilities. Similarly, we may not be able to mitigate other threats to the business such as developing effective contingency plans for potential supply interruptions. Any of the foregoing events or other unforeseen consequences of public health problems could materially adversely affect our business, result of operations, prospects, and financial condition. The full extent to which the COVID-19 outbreak will impact the Company’s business and operating results will depend on future developments that are highly uncertain and cannot be accurately predicted, including new information that may emerge concerning COVID-19 and actions taken to contain its spread or its impact.
The effects of the COVID-19 pandemic may remain prevalent for a significant period of time and may continue to adversely affect our business, results of operations and financial condition even after the COVID-19 outbreak has subsided. The extent to which the COVID-19 pandemic impacts us will depend on numerous evolving factors and future developments that we are not able to predict, including: the severity and duration of the outbreak; governmental, business and other actions (which could include limitations on our operations or mandates to provide services in a specified manner); the promotion of social distancing and the adoption of shelter-in-place orders affecting our ability to provide our services; the impact of the pandemic on economic activity; the extent and duration of the effect on consumer confidence and spending, customer demand and buying patterns; the health of and the effect on our workforce and our ability to meet staffing needs, particularly if members of our workforce, including key members of management, are quarantined as a result of exposure; any impairment in value of our tangible or intangible assets which could be recorded as a result of a weaker economic conditions; and the potential effects on our internal controls including those over financial reporting as a result of changes in working environments such as shelter-in-place and similar orders that are applicable to our employees and business partners, among others. Further, provisions for bad debt expense may increase given the financial difficulty faced by our business partners, which could, among other things, impact our ability to borrow under our credit facility. In addition, if the pandemic continues to create disruptions or turmoil in the credit or financial markets, it could adversely affect our ability to continue to meet our liquidity needs, all of which are highly uncertain and cannot be predicted.
ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
There were no unregistered sales of equity securities during the six months ended March 31, 2020. In addition, there were no shares of common stock purchased by us during the six months ended March 31, 2020.
ITEM 6.
EXHIBIT INDEX
Exhibit No.
Purchase and Sale Agreement dated February 4, 2020 by and between 4040 Earnings Way, LLC, and Indco, Inc. (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed March 4, 2020, as amended by the Company’s Current Report on Form 8-K/A filed March 6, 2020)
Third Amendment to Loan and Security Agreement dated March 4, 2020 by and between Santander Bank, N.A., Janel Group, Inc., Honor Worldwide Logistics LLC and Janel Corporation (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K filed March 4, 2020, as amended by the Company’s Current Report on Form 8-K/A filed March 6, 2020)
Loan Agreement dated April 19, 2020, by and between Janel Corporation and Santander Bank, N.A., together with the U.S. Small Business Administration Note dated April 19, 2020.
Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer (filed herewith)
Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer (filed herewith)
Section 1350 Certification of Principal Executive Officer (filed herewith)
Section 1350 Certification of Principal Financial Officer (filed herewith)
101
Interactive data files providing financial information from the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 for the six months ended March 31, 2020 and 2019 in XBRL (Extensible Business Reporting Language) pursuant to Rule 405 of Regulation S-T: (i) Consolidated Balance Sheets as of March 31, 2020 and September 30, 2019, (ii) Consolidated Statements of Operations for the six months ended March 31, 2020 and 2019, (iii) Consolidated Statement of Changes in Stockholders’ Equity for the six months ended March 31, 2020 and 2019, (iv) Consolidated Statements of Cash Flows for the six months ended March 31, 2020 and 2019, and (v) Notes to Consolidated Financial Statements.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Dated: May 11, 2020
JANEL CORPORATION
Registrant
/s/ Dominique Schulte
Dominique Schulte
Chairman, President and Chief Executive Officer
( Principal Executive Officer)

Dated: May 11 , 2 020
JANEL CORPORATION
Registrant
/s/ Vincent A. Verde
Vincent A. Verde
Principal Financial Officer, Treasurer and Secretary


44
TABLE OF CONTENTS
Part I -Item 1. Financial StatementsItem 2. Management S Discussion and Analysis Of Financial Condition and Results Of OperationsItem 4. Controls and ProceduresPart II - Other InformationPart II -Item 1. Legal ProceedingsItem 1A. Risk FactorsItem 2. Unregistered Sales Of Equity Securities and Use Of ProceedsItem 6. Exhibit Index

Exhibits

10.1 Purchase and Sale Agreement dated February 4, 2020 by and between 4040 Earnings Way, LLC, and Indco, Inc. (incorporated by reference to Exhibit 10.1 to the Companys Current Report on Form 8-K filed March 4, 2020, as amended by the Companys Current Report on Form 8-K/A filed March 6, 2020) 10.2 Third Amendment to Loan and Security Agreement dated March 4, 2020 by and between Santander Bank, N.A., Janel Group, Inc., Honor Worldwide Logistics LLC and Janel Corporation (incorporated by reference to Exhibit 10.2 to the Companys Current Report on Form 8-K filed March 4, 2020, as amended by the Companys Current Report on Form 8-K/A filed March 6, 2020) 10.3 Loan Agreement dated April 19, 2020, by and between Janel Corporation and Santander Bank, N.A., together with the U.S. Small Business Administration Note dated April 19, 2020. 31.1 Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer (filed herewith) 31.2 Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer (filed herewith) 32.1 Section 1350 Certification of Principal Executive Officer (filed herewith) 32.2 Section 1350 Certification of Principal Financial Officer (filed herewith)